Correction to: 2016 American Thyroid Association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis (Thyroid (2016) 26 (1343-1421) DOI: 10.1089/thy.2016.0229);2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis

Thyroid

Volumn 26, Issue 10, 2016, Pages 1343-1421

  Ross, Douglas S ^a   Burch, Henry B ^b   Cooper, David S ^c   Greenlee, M Carol ^d   Laurberg, Peter ^e   Maia, Ana Luiza ^f   Rivkees, Scott A ^g   Samuels, Mary ^h   Sosa, Julie Ann ⁱ   Stan, Marius N ^j   Walter, Martin A ^k  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b WALTER REED ARMY MEDICAL CENTER   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d Western Slope Endocrinology   (United States)

^e AALBORG UNIVERSITY   (Denmark)

^f HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

^g UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^h OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

ⁱ DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^j MAYO CLINIC   (United States)

^k UNIVERSITY OF BERN   (Switzerland)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHYROID AGENT; RADIOACTIVE IODINE;

ARTICLE; ENDOCRINE OPHTHALMOPATHY; EVIDENCE BASED MEDICINE; GRAVES DISEASE; HUMAN; HYPERTHYROIDISM; MEDICAL SOCIETY; PATIENT CARE; PRACTICE GUIDELINE; PREGNANT WOMAN; PRIORITY JOURNAL; THYROID ADENOMA; THYROID SURGERY; THYROTOXICOSIS; TOXIC GOITER; MULTIMODALITY CANCER THERAPY; PATHOPHYSIOLOGY; PERSONALIZED MEDICINE; SEVERITY OF ILLNESS INDEX; UNITED STATES;

COMBINED MODALITY THERAPY; EVIDENCE-BASED MEDICINE; HUMANS; HYPERTHYROIDISM; PRECISION MEDICINE; SEVERITY OF ILLNESS INDEX; SOCIETIES, MEDICAL; THYROTOXICOSIS; UNITED STATES;

EID: 84991406672     PISSN: 10507256     EISSN: 15579077     Source Type: Journal    
DOI: 10.1089/thy.2016.0229.correx     Document Type: Erratum

References (678)

1. Singer PA, Cooper DS, Levy EG, Ladenson PW, Braverman LE, Daniels G, Greenspan FS, McDougall IR, Nikolai TF 1995 Treatment guidelines for patients with hyperthyroidism and hypothyroidism. Standards of Care Committee, American Thyroid Association. JAMA 273:808-812.
2. Bahn RS, Burch HB, Cooper DS, Garber JR, Greenlee MC, Klein I, Laurberg P, McDougall IR, Montori VM, Rivkees SA, Ross DS, Sosa JA, Stan MN, American Thyroid Association, American Association of Clinical Endocrinologists 2011 Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists. Thyroid 21:593-646.
3. Atkins D, Best D, Briss PA, Eccles M, Falck-Ytter Y, Flottorp S, Guyatt GH, Harbour RT, Haugh MC, Henry D, Hill S, Jaeschke R, Leng G, Liberati A, Magrini N, Mason J, Middleton P, Mrukowicz J, O'Connell D, Oxman AD, Phillips B, Schunemann HJ, Edejer T, Varonen H, Vist GE, Williams JW Jr, Zaza S, GRADE Working Group 2004 Grading quality of evidence and strength of recommendations. BMJ 328:1490.
4. Guyatt GH, Oxman AD, Kunz R, Falck-Ytter Y, Vist GE, Liberati A, Schunemann HJ, GRADE Working Group 2008 Going from evidence to recommendations. BMJ 336:1049-1051.
5. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, Schunemann HJ, GRADE Working Group 2008 GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 336:924-926.
6. Guyatt G, Gutterman D, Baumann MH, Addrizzo-Harris D, Hylek EM, Phillips B, Raskob G, Lewis SZ, Schunemann H 2006 Grading strength of recommendations and quality of evidence in clinical guidelines: report from an American College of Chest Physicians task force. Chest 129:174-181.
7. Swiglo BA, Murad MH, Schunemann HJ, Kunz R, Vigersky RA, Guyatt GH, Montori VM2008 A case for clarity, consistency, and helpfulness: state-of-the-art clinical practice guidelines in endocrinology using the grading of recommendations, assessment, development, and evaluation system. J Clin Endocrinol Metab 93:666-673.
8. Berghout A, Wiersinga WM, Smits NJ, Touber JL 1990 Interrelationships between age, thyroid volume, thyroid nodularity, and thyroid function in patients with sporadic nontoxic goiter. Am J Med 89:602-608.
9. Gozu HI, Lublinghoff J, Bircan R, Paschke R 2010 Genetics and phenomics of inherited and sporadic nonautoimmune hyperthyroidism. Mol Cell Endocrinol 322: 125-134.
10. Martin FI, Deam DR 1996 Hyperthyroidism in elderly hospitalised patients. Clinical features and treatment outcomes. Med J Aust. 164:200-203.
11. Tibaldi JM, Barzel US, Albin J, Surks M 1986 Thyrotoxicosis in the very old. Am J Med 81:619-622.
12. Davis PJ, Davis FB 1974 Hyperthyroidism in patients over the age of 60 years. Clinical features in 85 patients. Medicine (Baltimore) 53:161-181.
13. Laurberg P, Pedersen KM, Vestergaard H, Sigurdsson G 1991 High incidence of multinodular toxic goitre in the elderly population in a low iodine intake area vs. high incidence of Graves' disease in the young in a high iodine intake area: comparative surveys of thyrotoxicosis epidemiology in East-Jutland Denmark and Iceland. J Intern Med 229:415-420.
14. Abraham-Nordling M, Bystrom K, Torring O, Lantz M, Berg G, Calissendorff J, Nystrom HF, Jansson S, Jorneskog G, Karlsson FA, Nystrom E, Ohrling H, Orn T, Hallengren B, Wallin G 2011 Incidence of hyperthyroidism in Sweden. Eur J Endocrinol 165:899-905.
15. Codaccioni JL, Orgiazzi J, Blanc P, Pugeat M, Roulier R, Carayon P 1988 Lasting remissions in patients treated for Graves' hyperthyroidism with propranolol alone: a pattern of spontaneous evolution of the disease. J Clin Endocrinol Metab. 67:656-662.
16. Schwartz F, Bergmann N, Zerahn B, Faber J 2013 Incidence rate of symptomatic painless thyroiditis presenting with thyrotoxicosis in Denmark as evaluated by consecutive thyroid scintigraphies. Scand J Clin Lab Invest 73:240-244.
17. Williams I, Ankrett VO, Lazarus JH, Volpe R 1983 Aetiology of hyperthyroidism in Canada and Wales. J Epidemiol Community Health 37:245-248.
18. Nikolai TF, Brosseau J, Kettrick MA, Roberts R, Beltaos E 1980 Lymphocytic thyroiditis with spontaneously resolving hyperthyroidism (silent thyroiditis). Arch Intern Med 140:478-482.
19. Miller KK, Daniels GH 2001 Association between lithium use and thyrotoxicosis caused by silent thyroiditis. Clin Endocrinol (Oxf) 55:501-508.
20. Roti E, Minelli R, Giuberti T, Marchelli S, Schianchi C, Gardini E, Salvi M, Fiaccadori F, Ugolotti G, Neri TM, Braverman LE 1996 Multiple changes in thyroid function in patients with chronic active HCV hepatitis treated with recombinant interferon-alpha. Am J Med 101:482-487.
21. Illouz F, Braun D, Briet C, Schweizer U, Rodien P 2014 Endocrine side-effects of anti-cancer drugs: thyroid effects of tyrosine kinase inhibitors. Eur J Endocrinol 171: R91-9.
22. Gerstein HC 1990 How common is postpartum thyroiditis? A methodologic overview of the literature. Arch Intern Med 150:1397-1400.
23. Cohen-Lehman J, Dahl P, Danzi S, Klein I 2010 Effects of amiodarone therapy on thyroid function. Nat Rev Endocrinol 6:34-41.
24. Fatourechi V, Aniszewski JP, Fatourechi GZ, Atkinson EJ, Jacobsen SJ 2003 Clinical features and outcome of subacute thyroiditis in an incidence cohort: Olmsted County, Minnesota, study. J Clin Endocrinol Metab 88: 2100-2105.
25. Klein I, Danzi S 2007 Thyroid disease and the heart. Circulation 116:1725-1735.
26. Burch HB, Wartofsky L 1993 Life-threatening thyrotoxicosis. Thyroid storm. Endocrinol Metab Clin North Am 22:263-277.
27. Hall P, Lundell G, Holm LE 1993 Mortality in patients treated for hyperthyroidism with iodine-131. Acta Endocrinol (Copenh) 128:230-234.
28. Trzepacz PT, Klein I, Roberts M, Greenhouse J, Levey GS 1989 Graves' disease: an analysis of thyroid hormone levels and hyperthyroid signs and symptoms. Am J Med 87:558-561.
29. Trzepacz PT, McCue M, Klein I, Levey GS, Greenhouse J 1988A psychiatric and neuropsychological study of patients with untreated Graves' disease. Gen Hosp Psychiatry 10:49-55.
30. Boelaert K, Torlinska B, Holder RL, Franklyn JA 2010 Older subjects with hyperthyroidism present with a paucity of symptoms and signs: a large cross-sectional study. J Clin Endocrinol Metab 95:2715-2726.
31. Ventrella S, Klein I 1994 Beta-adrenergic receptor blocking drugs in the management of hyperthyroidism. Endocrinologist 4:391-399.
32. European Heart Rhythm Association, Heart Rhythm Society, Fuster V, Ryden LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, Halperin JL, Le Heuzey JY, Kay GN, Lowe JE, Olsson SB, Prystowsky EN, Tamargo JL, Wann S, Smith SC Jr, Jacobs AK, Adams CD, Anderson JL, Antman EM, Hunt SA, Nishimura R, Ornato JP, Page RL, Riegel B, Priori SG, Blanc JJ, Budaj A, Camm AJ, Dean V, Deckers JW, Despres C, Dickstein K, Lekakis J, McGregor K, Metra M, Morais J, Osterspey A, Zamorano JL, American College of Cardiology, American Heart Association Task Force on Practice Guidelines, European Society of Cardiology Committee for Practice Guidelines, Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation 2006 ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation-executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation). J Am Coll Cardiol 48:854-906.
33. Brennan MD, Coenen-Schimke JM, Bigelow ML, Nair KS 2006 Changes in skeletal muscle protein metabolism and myosin heavy chain isoform messenger ribonucleic acid abundance after treatment of hyperthyroidism. J Clin Endocrinol Metab 91:4650-4656.
34. de los Santos ET, Starich GH, Mazzaferri EL 1989 Sensitivity, specificity, and cost-effectiveness of the sensitive thyrotropin assay in the diagnosis of thyroid disease in ambulatory patients. Arch Intern Med 149:526-532.
35. Spencer CA, LoPresti JS, Patel A, Guttler RB, Eigen A, Shen D, Gray D, Nicoloff JT 1990 Applications of a new chemiluminometric thyrotropin assay to subnormal measurement. J Clin Endocrinol Metab 70:453-460.
36. Rajatanavin R, Braverman LE 1983 Euthyroid hyperthyroxinemia. J Endocrinol Invest 6:493-505.
37. Rajatanavin R, Liberman C, Lawrence GD, D'Arcangues CM, Young RA, Emerson CH 1985 Euthyroid hyperthyroxinemia and thyroxine-binding prealbumin excess in islet cell carcinoma. J Clin Endocrinol Metab 61:17-21.
38. Spratt Di, Pont A, Miller MB, McDougall IR, Bayer MF, McLaughlin WT 1982 Hyperthyroxinemia in patients with acute psychiatric disorders. Am J Med 73:41-48.
39. Mordes JP, Blume FD, Boyer S, Zheng MR, Braverman LE 1983 High-altitude pituitary-thyroid dysfunction on Mount Everest. N Engl J Med 308:1135-1138.
40. Morley JE, Shafer RB, Elson MK, Slag MF, Raleigh MJ, Brammer GL, Yuwiler A, Hershman JM 1980 Amphetamine-induced hyperthyroxinemia. Ann Intern Med 93:707-709.
41. Kwok JS, Chan IH, Chan MH 2012 Biotin interference on TSH and free thyroid hormone measurement. Pathology 44:278-280.
42. Barbesino G 2016 Misdiagnosis of Graves' Disease with apparent severe hyperthyroidism in a patient taking biotin megadoses. Thyroid 26:860-863.
43. Socin HV, Chanson P, Delemer B, Tabarin A, Rohmer V, Mockel J, Stevenaert A, Beckers A 2003 The changing spectrum of TSH-secreting pituitary adenomas: diagnosis and management in 43 patients. Eur J Endocrinol 148: 433-442.
44. Dumitrescu AM, Refetoff S 2015 Impaired sensitivity to thyroid hormone: defects of transport, metabolism and action. In: De Groot LJ, Beck-Peccoz P, Chrousos G, Dungan K, Grossman A, Hershman JM, Kock C, McLachlan R, New M, Rebar R, Singer F, Vinik A, Weickert MO, eds. Endotext [Internet]. MDText. com, Inc., South Dartmouth, M.A.
45. McKee A, Peyerl F 2012 TSI assay utilization: impact on costs of Graves' hyperthyroidism diagnosis. Am J Manag Care 18:e1-14.
46. Summaria V, Salvatori M, Rufini V, Mirk P, Garganese MC, Romani M 1999 Diagnostic imaging in thyrotoxicosis. Rays 24:273-300.
47. Pedersen IB, Knudsen N, Perrild H, Ovesen L, Laurberg P 2001 TSH-receptor antibody measurement for differentiation of hyperthyroidism into Graves' disease and multinodular toxic goitre: a comparison of two competitive binding assays. Clin Endocrinol (Oxf) 55:381-390.
48. Bogazzi F, Vitti P 2008 Could improved ultrasound and power Doppler replace thyroidal radioiodine uptake to assess thyroid disease? Nat Clin Pract Endocrinol Metab 4:70-71.
49. Erdogan MF, Anil C, Cesur M, Baskal N, Erdogan G 2007 Color flow Doppler sonography for the etiologic diagnosis of hyperthyroidism. Thyroid 17:223-228.
50. Carle A, Knudsen N, Pedersen IB, Perrild H, Ovesen L, Rasmussen LB, Laurberg P 2013 Determinants of serum T4 and T3 at the time of diagnosis in nosological types of thyrotoxicosis: a population-based study. Eur J Endocrinol 169:537-545.
51. Shigemasa C, Abe K, Taniguchi S, Mitani Y, Ueda Y, Adachi T, Urabe K, Tanaka T, Yoshida A, Mashiba H 1987 Lower serum free thyroxine (T4) levels in painless thyroiditis compared with Graves' disease despite similar serum total T4 levels. J Clin Endocrinol Metab 65: 359-363.
52. Woolf PD 1980 Transient painless thyroiditis with hyperthyroidism: a variant of lymphocytic thyroiditis? Endocr Rev 1:411-420.
53. Mariotti S, Martino E, Cupini C, Lari R, Giani C, Baschieri L, Pinchera A 1982 Low serum thyroglobulin as a clue to the diagnosis of thyrotoxicosis factitia. N Engl J Med 307:410-412.
54. Bouillon R, Verresen L, Staels F, Bex M, De Vos P, De Roo M 1993 The measurement of fecal thyroxine in the diagnosis of thyrotoxicosis factitia. Thyroid 3:101-103.
55. Barbesino G, Tomer Y 2013 Clinical review: clinical utility of TSH receptor antibodies. J Clin Endocrinol Metab 98:2247-2255.
56. Kahaly GJ 2015 Bioassays for TSH receptor antibodies: quo vadis? Eur Thyroid J 4:3-5.
57. Tozzoli R, Bagnasco M, Giavarina D, Bizzaro N 2012 TSH receptor autoantibody immunoassay in patients with Graves' disease: improvement of diagnostic accuracy over different generations of methods. Systematic review and meta-analysis. Autoimmun Rev 12:107-113.
58. Tagami T, Yambe Y, Tanaka T, Tanaka T, Ogo A, Yoshizumi H, Kaise K, Higashi K, Tanabe M, Shimazu S, Usui T, Shimatsu A, Naruse M, BBGD Study Group 2012 Shortterm effects of beta-adrenergic antagonists and methimazole in new-onset thyrotoxicosis caused by Graves' disease. Intern Med 51:2285-2290.
59. Klein I, Becker DV, Levey GS 1994 Treatment of hyperthyroid disease. Ann Intern Med 121:281-288.
60. Burch HB, Burman KD, Cooper DS 2012A 2011 survey of clinical practice patterns in the management of Graves' disease. J Clin Endocrinol Metab 97:4549-4558.
61. Wartofsky L, Glinoer D, Solomon B, Nagataki S, Lagasse R, Nagayama Y, Izumi M 1991 Differences and similarities in the diagnosis and treatment of Graves' disease in Europe, Japan, and the United States. Thyroid 1:129-135.
62. Abraham-Nordling M, Torring O, Hamberger B, Lundell G, Tallstedt L, Calissendorff J, Wallin G 2005 Graves' disease: a long-term quality-of-life follow up of patients randomized to treatment with antithyroid drugs, radioiodine, or surgery. Thyroid 15:1279-1286.
63. Zen XX, Yuan Y, Liu Y, Wu TX, Han S 2007 Chinese herbal medicines for hyperthyroidism. Cochrane Database Syst Rev (2):CD005450.
64. Brito JP, Castaneda-Guarderas A, Gionfriddo MR, Ospina NS, Maraka S, Dean DS, Castro RM, Fatourechi V, Gharib H, Stan MN, Branda ME, Bahn RS, Montori VM 2015 Development and Pilot Testing of an Encounter Tool for Shared Decision Making About the Treatment of Graves' Disease. Thyroid 25:1191-1198.
65. Azizi F, Ataie L, Hedayati M, Mehrabi Y, Sheikholeslami F 2005 Effect of long-term continuous methimazole treatment of hyperthyroidism: comparison with radioiodine. Eur J Endocrinol 152:695-701.
66. Elbers L, Mourits M, Wiersinga W 2011 Outcome of very long-term treatment with antithyroid drugs in Graves' hyperthyroidism associated with Graves' orbitopathy. Thyroid 21:279-283.
67. Weingold AB 1983 Appendicitis in pregnancy. Clin Obstet Gynecol 26:801-809.
68. Kuy S, Roman SA, Desai R, Sosa JA 2009 Outcomes following thyroid and parathyroid surgery in pregnant women. Arch Surg 144:399-406; discussion 406.
69. Träisk F, Tallstedt L, Abraham-Nordling M, Andersson T, Berg G, Calissendorff J, Hallengren B, Hedner P, Lantz M, Nyström E, Ponjavic V, Taube A, Törring O, Wallin G, Asman P, Lundell G, Thyroid Study Group of TT 96 2009 Thyroid-associated ophthalmopathy after treatment for Graves' hyperthyroidism with antithyroid drugs or iodine-131. J Clin Endocrinol Metab 94:3700-3707.
70. McDermott MT, Kidd GS, Dodson LE Jr, Hofeldt FD 1983 Radioiodine-induced thyroid storm. Case report and literature review. Am J Med 75:353-359.
71. Walter MA, Briel M, Christ-Crain M, Bonnema SJ, Connell J, Cooper DS, Bucher HC, Muller-Brand J, Muller B 2007 Effects of antithyroid drugs on radioiodine treatment: systematic review and meta-analysis of randomised controlled trials. BMJ 334:514.
72. Akamizu T, Satoh T, Isozaki O, Suzuki A, Wakino S, Iburi T, Tsuboi K, Monden T, Kouki T, Otani H, Teramukai S, Uehara R, Nakamura Y, Nagai M, Mori M, Japan Thyroid Association 2012 Diagnostic criteria, clinical features, and incidence of thyroid storm based on nationwide surveys. Thyroid 22:661-679.
73. Delit C, Silver S, Yohalem SB, Segal RL 1961 Thyrocardiac disease and its management with radioactive iodine I-131. JAMA 176:262-267.
74. Shafer RB, Nuttall FQ 1975 Acute changes in thyroid function in patients treated with radioactive iodine. Lancet 2:635-637.
75. Burch HB, Solomon BL, Cooper DS, Ferguson P, Walpert N, Howard R 2001 The effect of antithyroid drug pretreatment on acute changes in thyroid hormone levels after (131)I ablation for Graves' disease. J Clin Endocrinol Metab 86:3016-3021.
76. Andrade VA, Gross JL, Maia AL 1999 Effect of methimazole pretreatment on serum thyroid hormone levels after radioactive treatment in Graves' hyperthyroidism. J Clin Endocrinol Metab 84:4012-4016.
77. Klein I 2008 Endocrine disorders and cardiovascular disease. In: Libby P, et al., eds. Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine, 8th edition. Saunders/Elsevier, Philadelphia, PA, pp 2033-2047.
78. Aro A, Huttunen JK, Lamberg BA, Pelkonen R, Ikkala E, Kuusisto A, Rissanen V, Salmi J, Tervonen S 1981 Comparison of propranolol and carbimazole as adjuncts to iodine-131 therapy of hyperthyroidism. Acta Endocrinol (Copenh) 96:321-327.
79. Walter MA, Christ-Crain M, Schindler C, Muller-Brand J, Muller B 2006 Outcome of radioiodine therapy without, on or 3 days off carbimazole: a prospective interventional three-group comparison. Eur J Nucl Med Mol Imaging 33:730-737.
80. Bonnema SJ, Bennedbaek FN, Gram J, Veje A, Marving J, Hegedus L 2003 Resumption of methimazole after 131I therapy of hyperthyroid diseases: effect on thyroid function and volume evaluated by a randomized clinical trial. Eur J Endocrinol 149:485-492.
81. Turner JG, Brownlie BE, Rogers TG 1976 Lithium as an adjunct to radioiodine therapy for thyrotoxicosis. Lancet 1:614-615.
82. Bogazzi F, Bartalena L, Brogioni S, Scarcello G, Burelli A, Campomori A, Manetti L, Rossi G, Pinchera A, Martino E 1999 Comparison of radioiodine with radioiodine plus lithium in the treatment of Graves' hyperthyroidism. J Clin Endocrinol Metab 84:499-503.
83. Bogazzi F, Giovannetti C, Fessehatsion R, Tanda ML, Campomori A, Compri E, Rossi G, Ceccarelli C, Vitti P, Pinchera A, Bartalena L, Martino E 2010 Impact of lithium on efficacy of radioactive iodine therapy for Graves' disease: a cohort study on cure rate, time to cure, and frequency of increased serum thyroxine after antithyroid drug withdrawal. J Clin Endocrinol Metab. 95:201-208.
84. Ross DS, Daniels GH, De Stefano P, Maloof F, Ridgway EC 1983 Use of adjunctive potassium iodide after radioactive iodine (131I) treatment of Graves' hyperthyroidism. J Clin Endocrinol Metab 57:250-253.
85. de Rooij A, Vandenbroucke JP, Smit JW, Stokkel MP, Dekkers OM 2009 Clinical outcomes after estimated versus calculated activity of radioiodine for the treatment of hyperthyroidism: systematic review and meta-analysis. Eur J Endocrinol 161:771-777.
86. Leslie WD, Ward L, Salamon EA, Ludwig S, Rowe RC, Cowden EA 2003A randomized comparison of radioiodine doses in Graves' hyperthyroidism. J Clin Endocrinol Metab 88:978-983.
87. Jarlov AE, Nygaard B, Hegedus L, Hartling SG, Hansen JM 1998 Observer variation in the clinical and laboratory evaluation of patients with thyroid dysfunction and goiter. Thyroid 8:393-398.
88. Peters H, Fischer C, Bogner U, Reiners C, Schleusener H 1997 Treatment of Graves' hyperthyroidism with radioiodine: results of a prospective randomized study. Thyroid 7:247-251.
89. Peters H, Fischer C, Bogner U, Reiners C, Schleusener H 1995 Radioiodine therapy of Graves' hyperthyroidism: standard vs. calculated 131iodine activity. Results from a prospective, randomized, multicentre study. Eur J Clin Invest 25:186-193.
90. Peters H, Fischer C, Bogner U, Reiners C, Schleusener H 1996 Reduction in thyroid volume after radioiodine therapy of Graves' hyperthyroidism: results of a prospective, randomized, multicentre study. Eur J Clin Invest 26:59-63.
91. Kaptein EM, Levenson H, Siegel ME, Gadallah M, Akmal M 2000 Radioiodine dosimetry in patients with end-stage renal disease receiving continuous ambulatory peritoneal dialysis therapy. J Clin Endocrinol Metab 85:3058-3064.
92. Kung AW, Yau CC, Cheng AC 1995 The action of methimazole and L-thyroxine in radioiodine therapy: a prospective study on the incidence of hypothyroidism. Thyroid 5:7-12.
93. Bonnema SJ, Bennedbaek FN, Veje A, Marving J, Hegedus L 2004 Propylthiouracil before 131I therapy of hyperthyroid diseases: effect on cure rate evaluated by a randomized clinical trial. J Clin Endocrinol Metab 89: 4439-4444.
94. Santos RB, Romaldini JH, Ward LS 2012A randomized controlled trial to evaluate the effectiveness of 2 regimens of fixed iodine (131I) doses for Graves disease treatment. Clin Nucl Med 37:241-244.
95. Braga M, Walpert N, Burch HB, Solomon BL, Cooper DS 2002 The effect of methimazole on cure rates after radioiodine treatment for Graves' hyperthyroidism: a randomized clinical trial. Thyroid 12:135-139.
96. Boelaert K, Maisonneuve P, Torlinska B, Franklyn JA 2013 Comparison of mortality in hyperthyroidism during periods of treatment with thionamides and after radioiodine. J Clin Endocrinol Metab 98:1869-1882.
97. Franklyn JA, Maisonneuve P, Sheppard MC, Betteridge J, Boyle P 1998 Mortality after the treatment of hyperthyroidism with radioactive iodine. N Engl J Med 338: 712-718.
98. Hieu TT, Russell AW, Cuneo R, Clark J, Kron T, Hall P, Doi SA 2012 Cancer risk after medical exposure to radioactive iodine in benign thyroid diseases: a metaanalysis. Endocr Relat Cancer 19:645-655.
99. Ceccarelli C, Canale D, Battisti P, Caglieresi C, Moschini C, Fiore E, Grasso L, Pinchera A, Vitti P 2006 Testicular function after 131I therapy for hyperthyroidism. Clin Endocrinol (Oxf) 65:446-452.
100. Read CH Jr, Tansey MJ, Menda Y 2004A 36-year retrospective analysis of the efficacy and safety of radioactive iodine in treating young Graves' patients. J Clin Endocrinol Metab 89:4229-4233.
101. Fisher WD, Voorhess ML, Gardner LI 1963 Congenital hypothyroidism in infant following maternal I-131 therapy with a review of hazards of environmental radioisotope contamination. J Pediatr 62:132-146.
102. Berg GE, Nystrom EH, Jacobsson L, Lindberg S, Lindstedt RG, Mattsson S, Niklasson CA, Noren AH, Westphal OG 1998 Radioiodine treatment of hyperthyroidism in a pregnant women. J Nucl Med 39:357-361.
103. Azizi F, Smyth P 2009 Breastfeeding and maternal and infant iodine nutrition. Clin Endocrinol (Oxf) 70:803-809.
104. Woodings S 2004 Radiation protection recommendations for I-131 thyrotoxicosis, thyroid cancer and phaeochromocytoma patients. Australas Phys Eng Sci Med 27: 118-128.
105. American Thyroid Association Taskforce On Radioiodine Safety, Sisson JC, Freitas J, McDougall IR, Dauer LT, Hurley JR, Brierley JD, Edinboro CH, Rosenthal D, Thomas MJ, Wexler JA, Asamoah E, Avram AM, Milas M, Greenlee C 2011 Radiation safety in the treatment of patients with thyroid diseases by radioiodine 131I: practice recommendations of the American Thyroid Association. Thyroid 21:335-346.
106. Stan MN, Durski JM, Brito JP, Bhagra S, Thapa P, Bahn RS 2013 Cohort study on radioactive iodine-induced hypothyroidism: implications for Graves' ophthalmopathy and optimal timing for thyroid hormone assessment. Thyroid 23:620-625.
107. Uy HL, Reasner CA, Samuels MH 1995 Pattern of recovery of the hypothalamic-pituitary-thyroid axis following radioactive iodine therapy in patients with Graves' disease. Am J Med 99:173-179.
108. Alexander EK, Larsen PR 2002 High dose of (131)I therapy for the treatment of hyperthyroidism caused by Graves' disease. J Clin Endocrinol Metab 87:1073-1077.
109. Cooper DS 2005 Antithyroid drugs. N Engl J Med 352: 905-917.
110. Cooper DS 1985 Propylthiouracil levels in hyperthyroid patients unresponsive to large doses. Evidence of poor patient compliance. Ann Intern Med 102:328-331.
111. Laurberg P 2006 Remission of Graves' disease during anti-thyroid drug therapy. Time to reconsider the mechanism? Eur J Endocrinol 155:783-786.
112. Abraham P, Avenell A, McGeoch SC, Clark LF, Bevan JS 2010 Antithyroid drug regimen for treating Graves' hyperthyroidism. Cochrane Database Syst Rev 1: CD003420.
113. Mazzaferri EL, Reynolds JC, Young RL, Thomas CN, Parisi AF 1976 Propranolol as primary therapy for thyrotoxicosis. Arch Intern Med 136:50-56.
114. Cooper DS 2003 Antithyroid drugs in the management of patients with Graves' disease: an evidence-based approach to therapeutic controversies. J Clin Endocrinol Metab 88: 3474-3481.
115. Nakamura H, Noh JY, Itoh K, Fukata S, Miyauchi A, Hamada N 2007 Comparison of methimazole and propylthiouracil in patients with hyperthyroidism caused by Graves' disease. J Clin Endocrinol Metab 92:2157-2162.
116. Page SR, Sheard CE, Herbert M, Hopton M, Jeffcoate WJ 1996A comparison of 20 or 40 mg per day of carbimazole in the initial treatment of hyperthyroidism. Clin Endocrinol (Oxf) 45:511-516.
117. Chen JJ, Ladenson PW 1986 Discordant hypothyroxinemia and hypertriiodothyroninemia in treated patients with hyperthyroid Graves' disease. J Clin Endocrinol Metab 63:102-106.
118. McCruden DC, Hilditch TE, Connell JM, McLellan AR, Robertson J, Alexander WD 1987 Duration of antithyroid action of methimazole estimated with an intravenous perchlorate discharge test. Clin Endocrinol (Oxf) 26: 33-39.
119. Abraham P, Avenell A, Park CM, Watson WA, Bevan JS 2005A systematic review of drug therapy for Graves' hyperthyroidism. Eur J Endocrinol 153:489-498.
120. Roti E, Robuschi G, Gardini E, Montermini M, Salvi M, Manfredi A, Gnudi A, Braverman LE 1988 Comparison of methimazole, methimazole and sodium ipodate, and methimazole and saturated solution of potassium iodide in the early treatment of hyperthyroid Graves' disease. Clin Endocrinol (Oxf) 28:305-314.
121. Sato S, Noh JY, Sato S, Suzuki M, Yasuda S, Matsumoto M, Kunii Y, Mukasa K, Sugino K, Ito K, Nagataki S, Taniyama M 2015 Comparison of efficacy and adverse effects between methimazole 15 mg+inorganic iodine 38 mg/day and methimazole 30 mg/day as initial therapy for Graves' disease patients with moderate to severe hyperthyroidism. Thyroid 25:43-50.
122. Sundaresh V, Brito JP, Wang Z, Prokop LJ, Stan MN, Murad MH, Bahn RS 2013 Comparative effectiveness of therapies for Graves' hyperthyroidism: a systematic review and network meta-analysis. J Clin Endocrinol Metab 98:3671-3677.
123. Otsuka F, Noh JY, Chino T, Shimizu T, Mukasa K, Ito K, Ito K, Taniyama M 2012 Hepatotoxicity and cutaneous reactions after antithyroid drug administration. Clin Endocrinol (Oxf) 77:310-315.
124. Andersohn F, Konzen C, Garbe E 2007 Systematic review: agranulocytosis induced by nonchemotherapy drugs. Ann Intern Med 146:657-665.
125. Meyer-Gessner M, Benker G, Lederbogen S, Olbricht T, Reinwein D 1994 Antithyroid drug-induced agranulocytosis: clinical experience with ten patients treated at one institution and review of the literature. J Endocrinol Invest 17:29-36.
126. Takata K, Kubota S, Fukata S, Kudo T, Nishihara E, Ito M, Amino N, Miyauchi A 2009 Methimazole-induced agranulocytosis in patients with Graves' disease is more frequent with an initial dose of 30 mg daily than with 15 mg daily. Thyroid 19:559-563.
127. Watanabe N, Narimatsu H, Noh JY, Yamaguchi T, Kobayashi K, Kami M, Kunii Y, Mukasa K, Ito K, Ito K 2012 Antithyroid drug-induced hematopoietic damage: a retrospective cohort study of agranulocytosis and pancytopenia involving 50, 385 patients with Graves' disease. J Clin Endocrinol Metab 97:E49-53.
128. Nakamura H, Miyauchi A, Miyawaki N, Imagawa J 2013 Analysis of 754 cases of antithyroid drug-induced agranulocytosis over 30 years in Japan. J Clin Endocrinol Metab 98:4776-4783.
129. Andersen SL, Olsen J, Laurberg P 2016 Antithyroid drug side effects in the population and in pregnancy. J Clin Endocrinol Metab 101:1606-1614.
130. Vilchez FJ, Torres I, Garcia-Valero A, Lopez-Tinoco C, de Los Santos A, Aguilar-Diosdado M 2006 Concomitant agranulocytosis and hepatotoxicity after treatment with carbimazole. Ann Pharmacother 40:2059-2063.
131. Woeber KA 2002 Methimazole-induced hepatotoxicity. Endocr Pract 8:222-224.
132. Ruiz JK, Rossi GV, Vallejos HA, Brenet RW, Lopez IB, Escribano AA 2003 Fulminant hepatic failure associated with propylthiouracil. Ann Pharmacother 37:224-228.
133. Rivkees SA, Szarfman A 2010 Dissimilar hepatotoxicity profiles of propylthiouracil and methimazole in children. J Clin Endocrinol Metab 95:3260-3267.
134. Wang MT, Lee WJ, Huang TY, Chu CL, Hsieh CH 2014 Antithyroid drug-related hepatotoxicity in hyperthyroidism patients: a population-based cohort study. Br J Clin Pharmacol 78:619-629.
135. Yang J, Li LF, Xu Q, Zhang J, Weng WW, Zhu YJ, Dong MJ 2015 Analysis of 90 cases of antithyroid drug-induced severe hepatotoxicity over 13 years in China. Thyroid 25: 278-283.
136. Cooper DS, Rivkees SA 2009 Putting propylthiouracil in perspective. J Clin Endocrinol Metab 94:1881-1882.
137. Kang AY, Baek YH, Sohn YJ, Lee SK, Son CH, Kim K, Yang DK 2006 Diffuse alveolar hemorrhage associated with antineutrophil cytoplasmic antibody levels in a pregnant woman taking propylthiouracil. Korean J Intern Med 21:240-243.
138. Noh JY, Yasuda S, Sato S, Matsumoto M, Kunii Y, Noguchi Y, Mukasa K, Ito K, Ito K, Sugiyama O, Kobayashi H, Nihojima S, Okazaki M, Yokoyama S 2009 Clinical characteristics of myeloperoxidase antineutrophil cytoplasmic antibody-associated vasculitis caused by antithyroid drugs. J Clin Endocrinol Metab 94:2806-2811.
139. Aloush V, Litinsky I, Caspi D, Elkayam O 2006 Propylthiouracil-induced autoimmune syndromes: two distinct clinical presentations with different course and management. Semin Arthritis Rheum 36:4-9.
140. Cin MO, Gursoy A, Morris Y, Aydintug OT, Kamel N, Gullu S 2009 Prevalence and clinical significance of antineutrophil cytoplasmic antibody in Graves' patients treated with propylthiouracil. Int J Clin Pract 63:299-302.
141. Gunton JE, Stiel J, Clifton-Bligh P, Wilmshurst E, McElduff A 2000 Prevalence of positive anti-neutrophil cytoplasmic antibody (ANCA) in patients receiving antithyroid medication. Eur J Endocrinol 142:587.
142. Gao Y, Chen M, Ye H, Guo XH, Zhao MH, Wang HY 2007 The target antigens of antineutrophil cytoplasmic antibodies (ANCA) induced by propylthiouracil. Int Immunopharmacol 7:55-60.
143. Balavoine AS, Glinoer D, Dubucquoi S, Wemeau JL 2015 Antineutrophil cytoplasmic antibody-positive small-vessel vasculitis associated with antithyroid drug therapy: how significant is the clinical problem? Thyroid 25:1273-1281.
144. Yazisiz V, Ongut G, Terzioglu E, Karayalcin U 2010 Clinical importance of antineutrophil cytoplasmic antibody positivity during propylthiouracil treatment. Int J Clin Pract 64:19-24.
145. Gao Y, Chen M, Ye H, Yu F, Guo XH, Zhao MH 2008 Long-term outcomes of patients with propylthiouracilinduced anti-neutrophil cytoplasmic auto-antibody-associated vasculitis. Rheumatology (Oxford) 47:1515-1520.
146. Gomez Cruz MJ, Jabbar M, Saini N, Eng D, Crawford B, Vazquez DM, Menon R, Chen M 2012 Severe hypoglycemia secondary to methimazole-induced insulin autoimmune syndrome in a 16 year old African-American male. Pediatr Diabetes 13:652-655.
147. Roh E, Kim YA, Ku EJ, Bae JH, Kim HM, Cho YM, Park YJ, Park KS, Kim SY, Kwak SH 2013 Two cases of methimazole-induced insulin autoimmune syndrome in Graves' disease. Endocrinol Metab (Seoul) 28:55-60.
148. Reed WW, Diehl LF 1991 Leukopenia, neutropenia, and reduced hemoglobin levels in healthy American blacks. Arch Intern Med 151:501-505.
149. Huang MJ, Liaw YF 1995 Clinical associations between thyroid and liver diseases. J Gastroenterol Hepatol 10: 344-350.
150. Ross, DS 2015 Patient information: antithyroid drugs (beyond the basics). Available at: www. uptodate. com/contents/antithyroid-drugs-beyond-the-basics?source= search-result&search=antithyroid+drugs&selectedTitle= 680 (accessed November 29, 2015).
151. American Thyroid Association 2016 Hyperthyroidism (overactive). Available at: www. thyroid. org/hyper thyroidism (accessed June 6, 2016).
152. Tajiri J, Noguchi S, Murakami T, Murakami N 1990 Antithyroid drug-induced agranulocytosis. The usefulness of routine white blood cell count monitoring. Arch Intern Med 150:621-624.
153. Ahmed K, Rao S, Simha V 2010 Antineutrophil cytoplasmic antibody-positive vasculitis in a patient with graves disease: cross-reaction between propylthiouracil and methimazole. Endocr Pract 16:449-451.
154. Pagsisihan DA, Andag-Silva A, Piores-Roderos O, Escobin MA 2015 Rapid preoperative preparation for thyroidectomy of a severely hyperthyroid patient with Graves' disease who developed agranulocytosis. J ASEAN Fed Endocrin Soc 30:48-52.
155. Liaw YF, Huang MJ, Fan KD, Li KL, Wu SS, Chen TJ 1993 Hepatic injury during propylthiouracil therapy in patients with hyperthyroidism. A cohort study. Ann Intern Med 118:424-428.
156. Cooper DS, Kaplan MM, Ridgway EC, Maloof F, Daniels GH 1979 Alkaline phosphatase isoenzyme patterns in hyperthyroidism. Ann Intern Med 90:164-168.
157. Bahn RS, Burch HS, Cooper DS, Garber JR, Greenlee CM, Klein IL, Laurberg P, McDougall IR, Rivkees SA, Ross D, Sosa JA, Stan MN 2009 The role of propylthiouracil in the management of Graves' disease in adults: report of a meeting jointly sponsored by the American Thyroid Association and the Food and Drug Administration. Thyroid 19:673-674.
158. Benyounes M, Sempoux C, Daumerie C, Rahier J, Geubel AP 2006 Propylthiouracyl-induced severe liver toxicity: an indication for alanine aminotransferase monitoring? World J Gastroenterol 12:6232-6234.
159. Kim HJ, Kim BH, Han YS, Yang I, Kim KJ, Dong SH, Kim HJ, Chang YW, Lee JI, Chang R 2001 The incidence and clinical characteristics of symptomatic propylthiouracilinduced hepatic injury in patients with hyperthyroidism: a single-center retrospective study. Am J Gastroenterol 96: 165-169.
160. Weiss M, Hassin D, Bank H 1980 Propylthiouracilinduced hepatic damage. Arch Intern Med 140:1184-1185.
161. Waseem M, Seshadri KG, Kabadi UM 1998 Successful outcome with methimazole and lithium combination therapy for propylthiouracil-induced hepatotoxicity. Endocr Pract 4:197-200.
162. Toderian AB, Lawson ML 2014 Use of antihistamines after serious allergic reaction to methimazole in pediatric Graves' disease. Pediatrics 133:e1401-1404.
163. Mazza E, Carlini M, Flecchia D, Blatto A, Zuccarini O, Gamba S, Beninati S, Messina M 2008 Long-term followup of patients with hyperthyroidism due to Graves' disease treated with methimazole. Comparison of usual treatment schedule with drug discontinuation vs continuous treatment with low methimazole doses: a retrospective study. J Endocrinol Invest 31:866-872.
164. Konishi T, Okamoto Y, Ueda M, Fukuda Y, Harusato I, Tsukamoto Y, Hamada N 2011 Drug discontinuation after treatment with minimum maintenance dose of an antithyroid drug in Graves' disease: a retrospective study on effects of treatment duration with minimum maintenance dose on lasting remission. Endocr J 58:95-100.
165. Kimball LE, Kulinskaya E, Brown B, Johnston C, Farid NR 2002 Does smoking increase relapse rates in Graves' disease? J Endocrinol Invest 25:152-157.
166. Allahabadia A, Daykin J, Holder RL, Sheppard MC, Gough SC, Franklyn JA 2000 Age and gender predict the outcome of treatment for Graves' hyperthyroidism. J Clin Endocrinol Metab 85:1038-1042.
167. Nedrebo BG, Holm PI, Uhlving S, Sorheim JI, Skeie S, Eide GE, Husebye ES, Lien EA, Aanderud S 2002 Predictors of outcome and comparison of different drug regimens for the prevention of relapse in patients with Graves' disease. Eur J Endocrinol 147:583-589.
168. Orunesu E, Bagnasco M, Salmaso C, Altrinetti V, Bernasconi D, Del Monte P, Pesce G, Marugo M, Mela GS 2004 Use of an artificial neural network to predict Graves' disease outcome within 2 years of drug withdrawal. Eur J Clin Invest 34:210-217.
169. Bolanos F, Gonzalez-Ortiz M, Duron H, Sanchez C 2002 Remission of Graves' hyperthyroidism treated with methimazole. Rev Invest Clin 54:307-310.
170. Kruljac I, Solter D, Vrkljan AM, Solter M 2015 Remission of Graves' disease is not related to early restoration of euthyroidism with high-dose methimazole therapy. Endocr Res 40:25-28.
171. Carella C, Mazziotti G, Sorvillo F, Piscopo M, Cioffi M, Pilla P, Nersita R, Iorio S, Amato G, Braverman LE, Roti E 2006 Serum thyrotropin receptor antibodies concentrations in patients with Graves' disease before, at the end of methimazole treatment, and after drug withdrawal: evidence that the activity of thyrotropin receptor antibody and/or thyroid response modify during the observation period. Thyroid 16:295-302.
172. Laurberg P, Wallin G, Tallstedt L, Abraham-Nordling M, Lundell G, Torring O 2008 TSH-receptor autoimmunity in Graves' disease after therapy with anti-thyroid drugs, surgery, or radioiodine: a 5-year prospective randomized study. Eur J Endocrinol 158:69-75.
173. Slingerland DW, Burrows BA 1979 Long-term antithyroid treatment in hyperthyroidism. JAMA 242:2408-2410.
174. Azizi F, Yousefi V, Bahrainian A, Sheikholeslami F, Tohidi M, Mehrabi Y 2012 Long-term continuous methimazole or radioiodine treatment for hyperthyroidism. Arch Iran Med 15:477-484.
175. Villagelin D, Romaldini JH, Santos RB, Milkos AB, Ward LS 2015 Outcomes in relapsed Graves' disease patients following radioiodine or prolonged low dose of methimazole treatment. Thyroid 25:1282-1290.
176. Vitti P, Rago T, Chiovato L, Pallini S, Santini F, Fiore E, Rocchi R, Martino E, Pinchera A 1997 Clinical features of patients with Graves' disease undergoing remission after antithyroid drug treatment. Thyroid 7:369-375.
177. Kobayashi S, Noh JY, Mukasa K, Kunii Y, Watanabe N, Matsumoto M, Ohye H, Suzuki M, Yoshihara A, Iwaku K, Sugino K, Ito K 2014 Characteristics of agranulocytosis as an adverse effect of antithyroid drugs in the second or later course of treatment. Thyroid 24:796-801.
178. Kim HK, Yoon JH, Jeon MJ, Kim TY, Shong YK, Lee MJ, Kim BH, Kim IJ, Joung JY, Kim SW, Chung JH, Kang HC 2015 Characteristics of Korean patients with antithyroid drug-induced agranulocytosis: a multicenter study in Korea. Endocrinol Metab (Seoul) 30:475-480.
179. Wood LC, Ingbar SH 1979 Hypothyroidism as a late sequela in patient with Graves' disease treated with antithyroid agents. J Clin Invest 64:1429-1436.
180. Langley RW, Burch HB 2003 Perioperative management of the thyrotoxic patient. Endocrinol Metab Clin North Am 32:519-534.
181. Erbil Y, Ozluk Y, Giris M, Salmaslioglu A, Issever H, Barbaros U, Kapran Y, Ozarmagan S, Tezelman S 2007 Effect of Lugol solution on thyroid gland blood flow and microvessel density in the patients with Graves' disease. J Clin Endocrinol Metab 92:2182-2189.
182. Ansaldo GL, Pretolesi F, Varaldo E, Meola C, Minuto M, Borgonovo G, Derchi LE, Torre GC 2000 Doppler evaluation of intrathyroid arterial resistances during preoperative treatment with Lugol's iodide solution in patients with diffuse toxic goiter. J Am Coll Surg 191:607-612.
183. Shinall MC Jr, Broome JT, Baker A, Solorzano CC 2013 Is potassium iodide solution necessary before total thyroidectomy for Graves disease? Ann Surg Oncol 20:2964-2967.
184. Baeza A, Aguayo J, Barria M, Pineda G 1991 Rapid preoperative preparation in hyperthyroidism. Clin Endocrinol (Oxf) 35:439-442.
185. Liel Y 2004 Rapid preoperative preparation for severe hyperthyroid Graves' disease. J Clin Endocrinol Metab 89:5866-7; author reply 5867.
186. Warmock A, Cooper DS, Burch HB 2014 Life-threatening thyrotoxicosis: thyroid storm and adverse effects of antithyroid drugs. In: Matflin D, ed. Medical Emergencies in Endocrinology. Endocrine Press, Endocrine Society, Washington, D.C.
187. Yang Y, Hwang S, Kim M, Lim Y, Kim MH, Lee S, Lim DJ, Kang MI, Cha BY 2015 Refractory Graves' disease successfully cured by adjunctive cholestyramine and subsequent total thyroidectomy. Endocrinol Metab (Seoul) 30:620-625.
188. Edafe O, Antakia R, Laskar N, Uttley L, Balasubramanian SP 2014 Systematic review and meta-analysis of predictors of post-thyroidectomy hypocalcaemia. Br J Surg 101:307-320.
189. Oltmann SC, Brekke AV, Schneider DF, Schaefer SC, Chen H, Sippel RS 2015 Preventing postoperative hypocalcemia in patients with Graves disease: a prospective study. Ann Surg Oncol 22:952-958.
190. Kim WW, Chung SH, Ban EJ, Lee CR, Kang SW, Jeong JJ, Nam KH, Chung WY, Park CS 2015 Is preoperative vitamin D deficiency a risk factor for postoperative symptomatic hypocalcemia in thyroid cancer patients undergoing total thyroidectomy plus central compartment neck dissection? Thyroid 25:911-918.
191. Genser L, Tresallet C, Godiris-Petit G, Li Sun Fui S, Salepcioglu H, Royer C, Menegaux F 2014 Randomized controlled trial of alfacalcidol supplementation for the reduction of hypocalcemia after total thyroidectomy. Am J Surg 207:39-45.
192. Testa A, Fant V, De Rosa A, Fiore GF, Grieco V, Castaldi P, Persiani R, Rausei S, D'ugo D, De Rosa G 2006 Calcitriol plus hydrochlorothiazide prevents transient postthyroidectomy hypocalcemia. Horm Metab Res 38:821-826.
193. Antakia R, Edafe O, Uttley L, Balasubramanian SP 2015 Effectiveness of preventative and other surgical measures on hypocalcemia following bilateral thyroid surgery: a systematic review and meta-analysis. Thyroid 25:95-106.
194. Palit TK, Miller CC 3rd, Miltenburg DM 2000 The efficacy of thyroidectomy for Graves' disease: a metaanalysis. J Surg Res 90:161-165.
195. Guo Z, Yu P, Liu Z, Si Y, Jin M 2013 Total thyroidectomy vs bilateral subtotal thyroidectomy in patients with Graves' diseases: a meta-analysis of randomized clinical trials. Clin Endocrinol (Oxf) 79:739-746.
196. Sung TY, Lee YM, Yoon JH, Chung KW, Hong SJ 2015 Long-term effect of surgery in Graves' disease: 20 years experience in a single institution. Int J Endocrinol 2015:542641.
197. Wilhelm SM, McHenry CR 2010 Total thyroidectomy is superior to subtotal thyroidectomy for management of Graves' disease in the United States. World J Surg 34: 1261-1264.
198. Sosa JA, Mehta PJ, Wang TS, Boudourakis L, Roman SA 2008A population-based study of outcomes from thyroidectomy in aging Americans: at what cost? J Am Coll Surg 206:1097-1105.
199. Sosa JA, Bowman HM, Tielsch JM, Powe NR, Gordon TA, Udelsman R 1998 The importance of surgeon experience for clinical and economic outcomes from thyroidectomy. Ann Surg 228:320-330.
200. Adam M, Thomas S, Youngwirth L, Hyslop T, Reed S, Scheri R, Roman S, Sosa JA 2016 Is there a minimum number of thyroidectomies a surgeon should perform to optimize patient outcomes. Ann Surg [March 8; epub ahead of print].
201. Roher HD, Goretzki PE, Hellmann P, Witte J 1999 Complications in thyroid surgery. Incidence and therapy. Chirurg 70:999-1010.
202. Abbas G, Dubner S, Heller KS 2001 Re-operation for bleeding after thyroidectomy and parathyroidectomy. Head Neck 23:544-546.
203. Jenkins K, Baker AB 2003 Consent and anaesthetic risk. Anaesthesia 58:962-984.
204. Husein M, Hier MP, Al-Abdulhadi K, Black M 2002 Predicting calcium status post thyroidectomy with early calcium levels. Otolaryngol Head Neck Surg 127:289-293.
205. Sywak MS, Palazzo FF, Yeh M, Wilkinson M, Snook K, Sidhu SB, Delbridge LW 2007 Parathyroid hormone assay predicts hypocalcaemia after total thyroidectomy. ANZ J Surg 77:667-670.
206. Wiseman JE, Mossanen M, Ituarte PH, Bath JM, Yeh MW 2010 An algorithm informed by the parathyroid hormone level reduces hypocalcemic complications of thyroidectomy. World J Surg 34:532-537.
207. Sabour S, Manders E, Steward DL 2009 The role of rapid PACU parathyroid hormone in reducing postthyroidectomy hypocalcemia. Otolaryngol Head Neck Surg 141:727-729.
208. Jumaily JS, Noordzij JP, Dukas AG, Lee SL, Bernet VJ, Payne RJ, McLeod IK, Hier MP, Black MJ, Kerr PD, Raffaelli M, Bellantone R, Lombardi CP, Dietrich MS 2010 Prediction of hypocalcemia after using 1-to 6-hour postoperative parathyroid hormone and calcium levels: an analysis of pooled individual patient data from 3 observational studies. Head Neck 32:427-434.
209. McLeod IK, Arciero C, Noordzij JP, Stojadinovic A, Peoples G, Melder PC, Langley R, Bernet V, Shriver CD 2006 The use of rapid parathyroid hormone assay in predicting postoperative hypocalcemia after total or completion thyroidectomy. Thyroid 16:259-265.
210. Julian MT, Balibrea JM, Granada ML, Moreno P, Alastrue A, Puig-Domingo M, Lucas A 2013 Intact parathyroid hormone measurement at 24 hours after thyroid surgery as predictor of parathyroid function at long term. Am J Surg 206:783-789.
211. Bellantone R, Lombardi CP, Raffaelli MP, Boscherini M, de Crea C, Alesina PF, Traini E, Princi P 2002 Videoassisted thyroidectomy. Asian J Surg 25:315-318.
212. Noordzij JP, Lee SL, Bernet VJ, Payne RJ, Cohen SM, McLeod IK, Hier MP, Black MJ, Kerr PD, Richards ML, Lo CY, Raffaelli M, Bellantone R, Lombardi CP, Cohen JI, Dietrich MS 2007 Early prediction of hypocalcemia after thyroidectomy using parathyroid hormone: an analysis of pooled individual patient data from nine observational studies. J Am Coll Surg 205:748-754.
213. Cote V, Sands N, Hier MP, Black MJ, Tamilia M, Mac-Namara E, Zhang X, Payne RJ 2008 Cost savings associated with post-thyroidectomy parathyroid hormone levels. Otolaryngol Head Neck Surg 138:204-208.
214. Annerbo M, Hultin H, Stalberg P, Hellman P 2014 Leftshifted relation between calcium and parathyroid hormone in Graves' disease. J Clin Endocrinol Metab 99:545-551.
215. Shah M, Bancos I, Thompson GB, Richards ML, Kasperbauer JL, Clarke BL, Drake MT, Stan MN 2015 Teriparatide therapy and reduced postoperative hospitalization for postsurgical hypoparathyroidism. JAMA Otolaryngol Head Neck Surg 141:822-827.
216. Wilson RB, Erskine C, Crowe PJ 2000 Hypomagnesemia and hypocalcemia after thyroidectomy: prospective study. World J Surg 24:722-726.
217. Roh JL, Park CI 2006 Routine oral calcium and vitamin D supplements for prevention of hypocalcemia after total thyroidectomy. Am J Surg 192:675-678.
218. Kaplan, EL, Angelos, P, Applewhite, M, Mercier, F, Grogan, R 2015 Chapter 21. Surgery of the thyroid. Thyroid Disease Manager. Available at: www. thyroidmanager . org/chapter/chapter-21surgery-of-the-thyroid/(accessed December 5, 2015).
219. Di Donna V, Santoro MG, de Waure C, Ricciato MP, Paragliola RM, Pontecorvi A, Corsello SM 2014A new strategy to estimate levothyroxine requirement after total thyroidectomy for benign thyroid disease. Thyroid 24: 1759-1764.
220. Carty SE, Doherty GM, Inabnet WB 3rd, Pasieka JL, Randolph GW, Shaha AR, Terris DJ, Tufano RP, Tuttle RM, Surgical Affairs Committee Of The American Thyroid Association 2012 American Thyroid Association statement on the essential elements of interdisciplinary communication of perioperative information for patients undergoing thyroid cancer surgery. Thyroid 22:395-399.
221. Stocker DJ, Burch HB 2003 Thyroid cancer yield in patients with Graves' disease. Minerva Endocrinol 28:205-212.
222. Kikuchi S, Noguchi S, Yamashita H, Uchino S, Kawamoto H 2006 Prognosis of small thyroid cancer in patients with Graves' disease. Br J Surg 93:434-439.
223. Cappelli C, Pirola I, De Martino E, Agosti B, Delbarba A, Castellano M, Rosei EA 2008 The role of imaging in Graves' disease: a cost-effectiveness analysis. Eur J Radiol 65:99-103.
224. Cakir M, Arici C, Alakus H, Altunbas H, Balci MK, Karayalcin U 2007 Incidental thyroid carcinoma in thyrotoxic patients treated by surgery. Horm Res 67:96-99.
225. Haugen BR M, Alexander EK, Bible KC, Doherty G, Mandel SJ, Nikiforov YE, Pacini F, Randolph G, Sawka A, Schlumberger M, Schuff KG, Sherman SI, Sosa JA, Steward D, Tuttle RM M, Wartofsky L 2016 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer. Thyroid 26:1-133.
226. Angell TE, Lechner MG, Nguyen CT, Salvato VL, Nicoloff JT, LoPresti JS 2015 Clinical features and hospital outcomes in thyroid storm: a retrospective cohort study. J Clin Endocrinol Metab 100:451-459.
227. Swee du S, Chng CL, Lim A 2015 Clinical characteristics and outcome of thyroid storm: a case series and review of neuropsychiatric derangements in thyrotoxicosis. Endocr Pract 21:182-189.
228. Nayak B, Burman K 2006 Thyrotoxicosis and thyroid storm. Endocrinol Metab Clin North Am 35:663-686, vii.
229. Abuid J, Larsen PR 1974 Triiodothyronine and thyroxine in hyperthyroidism. Comparison of the acute changes during therapy with antithyroid agents. J Clin Invest 54:201-208.
230. Cooper DS, Saxe VC, Meskell M, Maloof F, Ridgway EC 1982 Acute effects of propylthiouracil (PTU) on thyroidal iodide organification and peripheral iodothyronine deiodination: correlation with serum PTU levels measured by radioimmunoassay. J Clin Endocrinol Metab 54:101-107.
231. Chopra IJ, Williams DE, Orgiazzi J, Solomon DH 1975 Opposite effects of dexamethasone on serum concentrations of 3, 3, 5-triiodothyronine (reverse T3) and 3, 35-triiodothyronine (T3). J Clin Endocrinol Metab 41:911-920.
232. Cooper DS, Daniels GH, Ladenson PW, Ridgway EC 1982 Hyperthyroxinemia in patients treated with highdose propranolol. Am J Med 73:867-871.
233. Muller C, Perrin P, Faller B, Richter S, Chantrel F 2011 Role of plasma exchange in the thyroid storm. Ther Apher Dial 15:522-531.
234. Scholz GH, Hagemann E, Arkenau C, Engelmann L, Lamesch P, Schreiter D, Schoenfelder M, Olthoff D, Paschke R 2003 Is there a place for thyroidectomy in older patients with thyrotoxic storm and cardiorespiratory failure? Thyroid 13:933-940.
235. Tyer NM, Kim TY, Martinez DS 2014 Review of oral cholecystographic agents for the management of hyperthyroidism. Endocr Pract 20:1084-1092.
236. Plummer HS 1924 The value of iodine in exopthalmic goiter. J Iowa Med Soc 14:66-73.
237. Wood LC, Maloof F 1975 Thyroid failure after potassium iodide treatment of diffuse toxic goiter. Trans Assoc Am Physicians 88:235-247.
238. Emerson CH, Anderson AJ, Howard WJ, Utiger RD 1975 Serum thyroxine and triiodothyronine concentrations during iodide treatment of hyperthyroidism. J Clin Endocrinol Metab 40:33-36.
239. Wartofsky L, Ransil BJ, Ingbar SH 1970 Inhibition by iodine of the release of thyroxine from the thyroid glands of patients with thyrotoxicosis. J Clin Invest 49:78-86.
240. Wolff J, Chaikoff IL 1948 Plasma inorganic iodide, a chemical regulator of normal thyroid function. Endocrinology 42:468-471.
241. Philippou G, Koutras DA, Piperingos G, Souvatzoglou A, Moulopoulos SD 1992 The effect of iodide on serum thyroid hormone levels in normal persons, in hyperthyroid patients, and in hypothyroid patients on thyroxine replacement. Clin Endocrinol (Oxf) 36:573-578.
242. Vagenakis AG, Wang CA, Burger A, Maloof F, Braverman LE, Ingbar SH 1972 Iodide-induced thyrotoxicosis in Boston. N Engl J Med 287:523-527.
243. Okamura K, Sato K, Fujikawa M, Bandai S, Ikenoue H, Kitazono T 2014 Remission after potassium iodide therapy in patients with Graves' hyperthyroidism exhibiting thionamide-associated side effects. J Clin Endocrinol Metab 99:3995-4002.
244. Uchida T, Goto H, Kasai T, Komiya K, Takeno K, Abe H, Shigihara N, Sato J, Honda A, Mita T, Kanazawa A, Fujitani Y, Watada H 2014 Therapeutic effectiveness of potassium iodine in drug-naive patients with Graves' disease: a single-center experience. Endocrine 47:506-511.
245. Braverman LE, Woeber KA, Ingbar SH 1969 Induction of myxedema by iodide in patients euthyroid after radioiodin or surgical treatment of diffuse toxic goiter. N Engl J Med 281:816-821.
246. Erickson D, Gharib H, Li H, van Heerden JA 1998 Treatment of patients with toxic multinodular goiter. Thyroid 8:277-282.
247. Kang AS, Grant CS, Thompson GB, van Heerden JA 2002 Current treatment of nodular goiter with hyperthyroidism (Plummer's disease): surgery versus radioiodine. Surgery 132:916-23; discussion 923.
248. Nygaard B, Hegedus L, Ulriksen P, Nielsen KG, Hansen JM 1999 Radioiodine therapy for multinodular toxic goiter. Arch Intern Med 159:1364-1368.
249. Erkan ME, Demirin H, Asik M, Celbek G, Yildirim M, Aydin Y, Gungor A, Dogan AS 2012 Efficiency of radioactive I-131 therapy in geriatric patients with toxic nodular goiter. Aging Clin Exp Res 24:714-717.
250. Holm LE, Lundell G, Israelsson A, Dahlqvist I 1982 Incidence of hypothyroidism occurring long after iodine-131 therapy for hyperthyroidism. J Nucl Med 23: 103-107.
251. Yano Y, Sugino K, Akaishi J, Uruno T, Okuwa K, Shibuya H, Kitagawa W, Nagahama M, Ito K, Ito K 2011 Treatment of autonomously functioning thyroid nodules at a single institution: radioiodine therapy, surgery, and ethanol injection therapy. Ann Nucl Med 25:749-754.
252. Porterfield JR Jr, Thompson GB, Farley DR, Grant CS, Richards ML 2008 Evidence-based management of toxic multinodular goiter (Plummer's disease). World J Surg 32:1278-1284.
253. Bonnema SJ, Bertelsen H, Mortensen J, Andersen PB, Knudsen DU, Bastholt L, Hegedus L 1999 The feasibility of high dose iodine 131 treatment as an alternative to surgery in patients with a very large goiter: effect on thyroid function and size and pulmonary function. J Clin Endocrinol Metab 84:3636-3641.
254. Vidal-Trecan GM, Stahl JE, Eckman MH 2004 Radioiodine or surgery for toxic thyroid adenoma: dissecting an important decision. A cost-effectiveness analysis. Thyroid 14:933-945.
255. Vaiman M, Nagibin A, Hagag P, Kessler A, Gavriel H 2008 Hypothyroidism following partial thyroidectomy. Otolaryngol Head Neck Surg 138:98-100.
256. Verloop H, Louwerens M, Schoones JW, Kievit J, Smit JW, Dekkers OM 2012 Risk of hypothyroidism following hemithyroidectomy: systematic review and meta-analysis of prognostic studies. J Clin Endocrinol Metab 97:2243-2255.
257. Nygaard B, Hegedus L, Nielsen KG, Ulriksen P, Hansen JM 1999 Long-term effect of radioactive iodine on thyroid function and size in patients with solitary autonomously functioning toxic thyroid nodules. Clin Endocrinol(Oxf) 50:197-202.
258. Szumowski P, Rogowski F, Abdelrazek S, Kociura-Sawicka A, Sokolik-Ostasz A 2012 Iodine isotope 131I therapy for toxic nodular goitre: treatment efficacy parameters. Nucl Med Rev Cent East Eur. 15:7-13.
259. Ceccarelli C, Bencivelli W, Vitti P, Grasso L, Pinchera A 2005 Outcome of radioiodine-131 therapy in hyperfunctioning thyroid nodules: a 20 years' retrospective study. Clin Endocrinol (Oxf) 62:331-335.
260. Goldstein R, Hart IR 1983 Follow-up of solitary autonomous thyroid nodules treated with 131I. N Engl J Med 309:1473-1476.
261. Wahl RA, Rimpl I, Saalabian S, Schabram J 1998 Differentiated operative therapy of thyroid autonomy (Plummer's disease). Exp Clin Endocrinol Diabetes 106 Suppl 4:S78-84.
262. van Soestbergen MJ, van der Vijver JC, Graafland AD 1992 Recurrence of hyperthyroidism in multinodular goiter after long-term drug therapy: a comparison with Graves' disease. J Endocrinol Invest 15:797-800.
263. Nygaard B, Faber J, Veje A, Hegedus L, Hansen JM 1999 Transition of nodular toxic goiter to autoimmune hyperthyroidism triggered by 131I therapy. Thyroid 9:477-481.
264. Ron E, Doody MM, Becker DV, Brill AB, Curtis RE, Goldman MB, Harris BS 3rd, Hoffman DA, McConahey WM, Maxon HR, Preston-Martin S, Warshauer ME, Wong FL, Boice JD Jr 1998 Cancer mortality following treatment for adult hyperthyroidism. Cooperative Thyrotoxicosis Therapy Follow-up Study Group. JAMA 280: 347-355.
265. Hall P, Berg G, Bjelkengren G, Boice JD Jr, Ericsson UB, Hallquist A, Lidberg M, Lundell G, Tennvall J, Wiklund K 1992 Cancer mortality after iodine-131 therapy for hyperthyroidism. Int J Cancer 50:886-890.
266. Tarantini B, Ciuoli C, Di Cairano G, Guarino E, Mazzucato P, Montanaro A, Burroni L, Vattimo AG, Pacini F 2006 Effectiveness of radioiodine (131-I) as definitive therapy in patients with autoimmune and non-autoimmune hyperthyroidism. J Endocrinol Invest 29:594-598.
267. Becker DV, Hurley JR 1971 Complications of radioiodine treatment of hyperthyroidism. Semin Nucl Med 1:442-460.
268. Braverman L, Kloos RT, Law B Jr, Kipnes M, Dionne M, Magner J 2008 Evaluation of various doses of recombinant human thyrotropin in patients with multinodular goiters. Endocr Pract 14:832-839.
269. Koornstra JJ, Kerstens MN, Hoving J, Visscher KJ, Schade JH, Gort HB, Leemhuis MP 1999 Clinical and biochemical changes following 131I therapy for hyperthyroidism in patients not pretreated with antithyroid drugs. Neth J Med. 55:215-221.
270. Albino CC, Graf H, Sampaio AP, Vigario A, Paz-Filho GJ 2008 Thiamazole as an adjuvant to radioiodine for volume reduction of multinodular goiter. Expert Opin Investig Drugs 17:1781-1786.
271. Lee YY, Tam KW, Lin YM, Leu WJ, Chang JC, Hsiao CL, Hsu MT, Hsieh AT 2015 Recombinant human thyrotropin before (131) I therapy in patients with nodular goitre: a meta-analysis of randomized controlled trials. Clin Endocrinol (Oxf) 83:702-710.
272. Magner J 2008 Problems associated with the use of thyrogen in patients with a thyroid gland. N Engl J Med 359:1738-9; author reply 1739.
273. Nieuwlaat WA, Hermus AR, Sivro-Prndelj F, Corstens FH, Huysmans DA 2001 Pretreatment with recombinant human TSH changes the regional distribution of radioiodine on thyroid scintigrams of nodular goiters. J Clin Endocrinol Metab 86:5330-5336.
274. Gharib H, Papini E, Paschke R, Duick DS, Valcavi R, Hegedus L, Vitti P, AACE/AME/ETA Task Force on Thyroid Nodules 2010 American Association of Clinical Endocrinologists, Associazione Medici Endocrinologi, and European Thyroid Association Medical guidelines for clinical practice for the diagnosis and management of thyroid nodules: executive summary of recommendations. Endocr Pract 16:468-475.
275. Cerci C, Cerci SS, Eroglu E, Dede M, Kapucuoglu N, Yildiz M, Bulbul M 2007 Thyroid cancer in toxic and non-toxic multinodular goiter. J Postgrad Med 53: 157-160.
276. Camargo R, Corigliano S, Friguglietti C, Gauna A, Harach R, Munizaga F, Niepomniszcze H, Pitoia F, Pretell E, Vaisman M, Ward LS, Wohllk N, Tomimori E, Latin American thyroid society 2009 Latin American thyroid society recommendations for the management of thyroid nodules. Arq Bras Endocrinol Metabol 53:1167-1175.
277. Rosario PW, Ward LS, Carvalho GA, Graf H, Maciel RM, Maciel LM, Maia AL, Vaisman M, Sociedade Brasileira de Endocrinologia e Metabologia 2013 Thyroid nodules and differentiated thyroid cancer: update on the Brazilian consensus. Arq Bras Endocrinol Metabol 57:240-264.
278. Ferrari C, Reschini E, Paracchi A 1996 Treatment of the autonomous thyroid nodule: a review. Eur J Endocrinol 135:383-390.
279. Zakavi SR, Mousavi Z, Davachi B 2009 Comparison of four different protocols of I-131 therapy for treating single toxic thyroid nodule. Nucl Med Commun 30:169-175.
280. Meller J, Siefker U, Hamann A, Hufner M 2006 Incidence of radioiodine induced Graves' disease in patients with multinodular toxic goiter. Exp Clin Endocrinol Diabetes 114:235-239.
281. Dobyns BM 1978 Prevention and management of hyperthyroid storm. World J Surg 2:293-306.
282. Hamilton WF, Forrest AL, Gunn A, Peden NR, Feely J 1984 Beta-adrenoceptor blockade and anaesthesia for thyroidectomy. Anaesthesia 39:335-342.
283. Fleisher LA 2000 Risk of anesthesia. In: Miller RD, ed. Anesthesia, 5th edition. Churchill Livingstone, Philadelphia, PA, pp 795-823.
284. Siegel RD, Lee SL 1998 Toxic nodular goiter. Toxic adenoma and toxic multinodular goiter. Endocrinol Metab Clin North Am 27:151-168.
285. Cirocchi R, Trastulli S, Randolph J, Guarino S, Di Rocco G, Arezzo A, D'Andrea V, Santoro A, Barczynski M, Avenia N 2015 Total or near-total thyroidectomy versus subtotal thyroidectomy for multinodular non-toxic goitre in adults. Cochrane Database Syst Rev 8:CD010370.
286. Reeve TS, Delbridge L, Cohen A, Crummer P 1987 Total thyroidectomy. The preferred option for multinodular goiter. Ann Surg 206:782-786.
287. Mishra A, Agarwal A, Agarwal G, Mishra SK 2001 Total thyroidectomy for benign thyroid disorders in an endemic region. World J Surg 25:307-310.
288. Pappalardo G, Guadalaxara A, Frattaroli FM, Illomei G, Falaschi P 1998 Total compared with subtotal thyroidectomy in benign nodular disease: personal series and review of published reports. Eur J Surg 164:501-506.
289. Hisham AN, Azlina AF, Aina EN, Sarojah A 2001 Total thyroidectomy: the procedure of choice for multinodular goitre. Eur J Surg 167:403-405.
290. al-Suliman NN, Ryttov NF, Qvist N, Blichert-Toft M, Graversen HP 1997 Experience in a specialist thyroid surgery unit: a demographic study, surgical complications, and outcome. Eur J Surg 163:13-20.
291. Thomusch O, Machens A, Sekulla C, Ukkat J, Lippert H, Gastinger I, Dralle H 2000 Multivariate analysis of risk factors for postoperative complications in benign goiter surgery: prospective multicenter study in Germany. World J Surg 24:1335-1341.
292. Bliss R, Patel N, Guinea A, Reeve TS, Delbridge L 1999 Age is no contraindication to thyroid surgery. Age Ageing 28:363-366.
293. Sosa JA, Mehta PJ, Wang TS, Yeo HL, Roman SA 2007 Racial disparities in clinical and economic outcomes from thyroidectomy. Ann Surg 246:1083-1091.
294. Spanknebel K, Chabot JA, DiGiorgi M, Cheung K, Lee S, Allendorf J, Logerfo P 2005 Thyroidectomy using local anesthesia: a report of 1, 025 cases over 16 years. J Am Coll Surg 201:375-385.
295. Stoll SJ, Pitt SC, Liu J, Schaefer S, Sippel RS, Chen H 2009 Thyroid hormone replacement after thyroid lobectomy. Surgery 146:554-8; discussion 558-60.
296. Matte R, Ste-Marie LG, Comtois R, D'Amour P, Lacroix A, Chartrand R, Poisson R, Bastomsky CH 1981 The pituitary-thyroid axis after hemithyroidectomy in euthyroid man. J Clin Endocrinol Metab 53:377-380.
297. Laurberg P, Buchholtz Hansen PE, Iversen E, Eskjaer Jensen S, Weeke J 1986 Goitre size and outcome of medical treatment of Graves' disease. Acta Endocrinol (Copenh) 111:39-43.
298. Takats KI, Szabolcs I, Foldes J, Foldes I, Ferencz A, Rimanoczy E, Goth M, Dohan O, Kovacs L, Szilagyi G 1999 The efficacy of long term thyrostatic treatment in elderly patients with toxic nodular goitre compared to radioiodine therapy with different doses. Exp Clin Endocrinol Diabetes 107:70-74.
299. Tarantino L, Francica G, Sordelli I, Sperlongano P, Parmeggiani D, Ripa C, Parmeggiani U 2008 Percutaneous ethanol injection of hyperfunctioning thyroid nodules: long-term follow-up in 125 patients. AJR Am. J. Roentgenol. 190:800-808.
300. Monzani F, Caraccio N, Goletti O, Lippolis PV, Casolaro A, Del Guerra P, Cavina E, Miccoli P 1997 Five-year follow-up of percutaneous ethanol injection for the treatment of hyperfunctioning thyroid nodules: a study of 117 patients. Clin Endocrinol(Oxf) 46:9-15.
301. Zingrillo M, Torlontano M, Ghiggi MR, Frusciante V, Varraso A, Liuzzi A, Trischitta V 2000 Radioiodine and percutaneous ethanol injection in the treatment of large toxic thyroid nodule: a long-term study. Thyroid 10:985-989.
302. Bennedbaek FN, Hegedus L 1999 Percutaneous ethanol injection therapy in benign solitary solid cold thyroid nodules: a randomized trial comparing one injection with three injections. Thyroid 9:225-233.
303. Mauz PS, Maassen MM, Braun B, Brosch S 2004 How safe is percutaneous ethanol injection for treatment of thyroid nodule? Report of a case of severe toxic necrosis of the larynx and adjacent skin. Acta Otolaryngol 124:1226-1230.
304. Ha EJ, Baek JH, Kim KW, Pyo J, Lee JH, Baek SH, Dossing H, Hegedus L 2015 Comparative efficacy of radiofrequency and laser ablation for the treatment of benign thyroid nodules: systematic review including traditional pooling and bayesian network meta-analysis. J Clin Endocrinol Metab 100:1903-1911.
305. Sung JY, Baek JH, Jung SL, Kim JH, Kim KS, Lee D, Kim WB, Na DG 2015 Radiofrequency ablation for autonomously functioning thyroid nodules: a multicenter study. Thyroid 25:112-117.
306. Che Y, Jin S, Shi C, Wang L, Zhang X, Li Y, Baek JH 2015 Treatment of benign thyroid nodules: comparison of surgery with radiofrequency ablation. AJNR Am J Neuroradiol 36:1321-1325.
307. Ji Hong M, Baek JH, Choi YJ, Lee JH, Lim HK, Shong YK, Hong SJ 2015 Radiofrequency ablation is a thyroid function-preserving treatment for patients with bilateral benign thyroid nodules. J Vasc Interv Radiol 26:55-61.
308. Ma C, Kuang A, Xie J, Liu G 2008 Radioiodine treatment for pediatric Graves' disease. Cochrane Database Syst Rev 3:CD006294.
309. Rivkees SA, Sklar C, Freemark M 1998 Clinical review 99: the management of Graves' disease in children, with special emphasis on radioiodine treatment. J Clin Endocrinol Metab 83:3767-3776.
310. Levy WJ, Schumacher OP, Gupta M 1988 Treatment of childhood Graves' disease. A review with emphasis on radioiodine treatment. Cleve Clin J Med 55:373-382.
311. Lee JA, Grumbach MM, Clark OH 2007 The optimal treatment for pediatric Graves' disease is surgery. J Clin Endocrinol Metab 92:801-803.
312. Rivkees SA, Dinauer C 2007 An optimal treatment for pediatric Graves' disease is radioiodine. J Clin Endocrinol Metab 92:797-800.
313. Freitas JE, Swanson DP, Gross MD, Sisson JC 1979 Iodine-131: optimal therapy for hyperthyroidism in children and adolescents? J Nucl Med 20:847-850.
314. Boice JD Jr 2005 Radiation-induced thyroid cancer-what's new? J Natl Cancer Inst 97:703-705.
315. Boice JD Jr 2006 Thyroid disease 60 years after Hiroshima and 20 years after Chernobyl. JAMA 295: 1060-1062.
316. Sosa JA, Tuggle CT, Wang TS, Thomas DC, Boudourakis L, Rivkees S, Roman SA 2008 Clinical and economic outcomes of thyroid and parathyroid surgery in children. J Clin Endocrinol Metab 93:3058-3065.
317. Tuggle CT, Roman SA, Wang TS, Boudourakis L, Thomas DC, Udelsman R, Ann Sosa J 2008 Pediatric endocrine surgery: who is operating on our children? Surgery 144:869-877; discussion 877.
318. Breuer CK, Solomon D, Donovan P, Rivkees SA, Udelsman R 2013 Effect of patient age on surgical outcomes for Graves' disease: a case-control study of 100 consecutive patients at a high volume thyroid surgical center. Int J Pediatr Endocrinol 2013:1-9856-2013-1.
319. Nicholas WC, Fischer RG, Stevenson RA, Bass JD 1995 Single daily dose of methimazole compared to every 8 hours propylthiouracil in the treatment of hyperthyroidism. South Med J 88:973-976.
320. Sato H, Harada S, Yokoya S, Tanaka T, Asayama K, Mori M, Sasaki N 2007 Treatment for childhood-onset Graves' disease in Japan: results of a nationwide questionnaire survey of pediatric endocrinologists and thyroidologists. Thyroid 17:67-72.
321. Dotsch J, Siebler T, Hauffa BP, Doeker B, Andler W, Bettendorf M, Heinrich U, Gohlke B, Albers N, Willgerodt H, Kiess W 2000 Diagnosis and management of juvenile hyperthyroidism in Germany: a retrospective multicenter study. J Pediatr Endocrinol Metab 13:879-885.
322. Dotsch J, Rascher W, Dorr HG 2003 Graves disease in childhood: a review of the options for diagnosis and treatment. Paediatr Drugs 5:95-102.
323. Razvi S, Vaidya B, Perros P, Pearce SH 2006 What is the evidence behind the evidence-base? The premature death of block-replace antithyroid drug regimens for Graves' disease. Eur J Endocrinol 154:783-786.
324. Cooper DS, Goldminz D, Levin AA, Ladenson PW, Daniels GH, Molitch ME, Ridgway EC 1983 Agranulocytosis associated with antithyroid drugs. Effects of patient age and drug dose. Ann Intern Med 98:26-29.
325. van Veenendaal NR, Rivkees SA 2011 Treatment of pediatric Graves' disease is associated with excessive weight gain. J Clin Endocrinol Metab 96:3257-3263.
326. Rivkees SA, Mattison DR 2009 Propylthiouracil (PTU) Hepatoxicity in Children and Recommendations for Discontinuation of Use. Int J Pediatr Endocrinol 2009: 132041.
327. Rivkees SA 2014 Pediatric Graves' disease: management in the post-propylthiouracil era. Int J Pediatr Endocrinol 2014:10-9856-2014-10. Epub 2014 Jun 16.
328. Rivkees SA 2010 63 Years and 715 days to the ''boxed warning'': unmasking of the propylthiouracil problem. Int J Pediatr Endocrinol 2010:658267.
329. Wada N, Mukai M, Kohno M, Notoya A, Ito T, Yoshioka N 2002 Prevalence of serum anti-myeloperoxidase antineutrophil cytoplasmic antibodies (MPO-ANCA) in patients with Graves' disease treated with propylthiouracil and thiamazole. Endocr J 49:329-334.
330. Sato H, Hattori M, Fujieda M, Sugihara S, Inomata H, Hoshi M, Miyamoto S 2000 High prevalence of antineutrophil cytoplasmic antibody positivity in childhood onset Graves' disease treated with propylthiouracil. J Clin Endocrinol Metab 85:4270-4273.
331. Salpeter SR, Ormiston TM, Salpeter EE 2002 Cardioselective beta-blockers in patients with reactive airway disease: a meta-analysis. Ann Intern Med 137:715-725.
332. Rivkees SA, Stephenson K, Dinauer C 2010 Adverse events associated with methimazole therapy of Graves' disease in children. Int J Pediatr Endocrinol 2010:176970.
333. Hamburger JI 1985 Management of hyperthyroidism in children and adolescents. J Clin Endocrinol Metab 60: 1019-1024.
334. Kaguelidou F, Alberti C, Castanet M, Guitteny MA, Czernichow P, Leger J, French Childhood Graves' Disease Study Group 2008 Predictors of autoimmune hyperthyroidism relapse in children after discontinuation of antithyroid drug treatment. J Clin Endocrinol Metab 93:3817-3826.
335. Tajiri J, Noguchi S 2005 Antithyroid drug-induced agranulocytosis: how has granulocyte colony-stimulating factor changed therapy? Thyroid 15:292-297.
336. Lazar L, Kalter-Leibovici O, Pertzelan A, Weintrob N, Josefsberg Z, Phillip M 2000 Thyrotoxicosis in prepubertal children compared with pubertal and postpubertal patients. J Clin Endocrinol Metab 85:3678-3682.
337. Leger J, Gelwane G, Kaguelidou F, Benmerad M, Alberti C, French Childhood Graves' Disease Study Group 2012 Positive impact of long-term antithyroid drug treatment on the outcome of children with Graves' disease: national longterm cohort study. J Clin Endocrinol Metab 97:110-119.
338. Weetman AP 2006 Graves' hyperthyroidism: how long should antithyroid drug therapy be continued to achieve remission? Nat Clin Pract Endocrinol Metab 2:2-3.
339. Glaser NS, Styne DM, Organization of Pediatric Endocrinologists of Northern California Collaborative Graves' Disease Study Group 2008 Predicting the likelihood of remission in children with Graves' disease: a prospective, multicenter study. Pediatrics 121:e481-8.
340. Shulman Di, Muhar I, Jorgensen EV, Diamond FB, Bercu BB, Root AW 1997 Autoimmune hyperthyroidism in prepubertal children and adolescents: comparison of clinical and biochemical features at diagnosis and responses to medical therapy. Thyroid 7:755-760.
341. Lippe BM, Landaw EM, Kaplan SA 1987 Hyperthyroidism in children treated with long term medical therapy: twenty-five percent remission every two years. J Clin Endocrinol Metab 64:1241-1245.
342. Glaser NS, Styne DM 1997 Predictors of early remission of hyperthyroidism in children. J Clin Endocrinol Metab 82:1719-1726.
343. Ohye H, Minagawa A, Noh JY, Mukasa K, Kunii Y, Watanabe N, Matsumoto M, Suzuki M, Yoshihara A, Ito K, Ito K 2014 Antithyroid drug treatment for Graves' disease in children: a long-term retrospective study at a single institution. Thyroid 24:200-207.
344. Jevalikar G, Solis J, Zacharin M 2014 Long-term outcomes of pediatric Graves' disease. J Pediatr Endocrinol Metab 27:1131-1136.
345. Havgaard Kjaer R, Smedegard Andersen M, Hansen D 2015 Increasing incidence of juvenile thyrotoxicosis in Denmark: a nationwide study, 1998-2012. Horm Res Paediatr 84:102-107.
346. Smith J, Brown RS 2007 Persistence of thyrotropin (TSH) receptor antibodies in children and adolescents with Graves' disease treated using antithyroid medication. Thyroid 17:1103-1107.
347. Kadmon PM, Noto RB, Boney CM, Goodwin G, Gruppuso PA 2001 Thyroid storm in a child following radioactive iodine (RAI) therapy: a consequence of RAI versus withdrawal of antithyroid medication. J Clin Endocrinol Metab 86:1865-1867.
348. Rohrs HJ 3rd, Silverstein JH, Weinstein DA, Amdur RJ, Haller MJ 2014 Thyroid storm following radioactive iodine (RAI) therapy for pediatric Graves disease. Am J Case Rep 15:212-215.
349. Rivkees SA, Cornelius EA 2003 Influence of iodine-131 dose on the outcome of hyperthyroidism in children. Pediatrics 111:745-749.
350. Nebesio TD, Siddiqui AR, Pescovitz OH, Eugster EA 2002 Time course to hypothyroidism after fixed-dose radioablation therapy of Graves' disease in children. J Pediatr 141:99-103.
351. Dobyns BM, Sheline GE, Workman JB, Tompkins EA, McConahey WM, Becker DV 1974 Malignant and benign neoplasms of the thyroid in patients treated for hyperthyroidism: a report of the cooperative thyrotoxicosis therapy follow-up study. J Clin Endocrinol Metab 38:976-998.
352. Ron E, Lubin JH, Shore RE, Mabuchi K, Modan B, Pottern LM, Schneider AB, Tucker MA, Boice JD Jr 1995 Thyroid cancer after exposure to external radiation: a pooled analysis of seven studies. Radiat Res 141:259-277.
353. Ron E, Lubin JH, Shore RE, Mabuchi K, Modan B, Pottern LM, Schneider AB, Tucker MA, Boice JD Jr 2012 Thyroid cancer after exposure to external radiation: a pooled analysis of seven studies. 1995. Radiat Res 178: AV43-60.
354. Boice JD Jr 1998 Radiation and thyroid cancer: what more can be learned? Acta Oncol 37:321-324.
355. Ueda D 1990 Normal volume of the thyroid gland in children. J Clin Ultrasound 18:455-462.
356. Kalinyak JE, McDougall IR 2003 How should the dose of iodine-131 be determined in the treatment of Graves' hyperthyroidism? J Clin Endocrinol Metab 88:975-977.
357. Sigurdson AJ, Ronckers CM, Mertens AC, Stovall M, Smith SA, Liu Y, Berkow RL, Hammond S, Neglia JP, Meadows AT, Sklar CA, Robison LL, Inskip PD 2005 Primary thyroid cancer after a first tumour in childhood (the Childhood Cancer Survivor Study): a nested casecontrol study. Lancet 365:2014-2023.
358. Davis S, Kopecky KJ, Hamilton TE, Onstad L, Hanford Thyroid Disease Study Team 2004 Thyroid neoplasia, autoimmune thyroiditis, and hypothyroidism in persons exposed to iodine 131 from the hanford nuclear site. JAMA 292:2600-2613.
359. Dickman PW, Holm LE, Lundell G, Boice JD Jr, Hall P 2003 Thyroid cancer risk after thyroid examination with 131I: a population-based cohort study in Sweden. Int J Cancer 106:580-587.
360. Shore RE 1992 Issues and epidemiological evidence regarding radiation-induced thyroid cancer. Radiat Res 131:98-111.
361. Toohey RE, Stabin MG, Watson EE 2000 The AAPM/RSNA physics tutorial for residents: internal radiation dosimetry: principles and applications. Radiographics 20: 533-46; quiz 531-2.
362. Committee to assess health risks from exposure to low levels of ionizing radiation, Board on Radiation Effects, Research Division on Earth and Life Sciences, National Research Council of the National Academies. 2006 Health risks from exposure to low levels of ionizing radiation: BIER VII-Phase 2. National Academies Press, Washington, D.C.
363. Miccoli P, Vitti P, Rago T, Iacconi P, Bartalena L, Bogazzi F, Fiore E, Valeriano R, Chiovato L, Rocchi R, Pinchera A 1996 Surgical treatment of Graves' disease: subtotal or total thyroidectomy? Surgery 120:1020-4; discussion 1024-5.
364. Sherman J, Thompson GB, Lteif A, Schwenk WF 2nd, van Heerden J, Farley DR, Kumar S, Zimmerman D, Churchward M, Grant CS 2006 Surgical management of Graves disease in childhood and adolescence: an institutional experience. Surgery 140:1056-1061; discussion 1061-1062.
365. Hollowell JG, Staehling NW, Flanders WD, Hannon WH, Gunter EW, Spencer CA, Braverman LE 2002 Serum TSH, T(4), and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III). J Clin Endocrinol Metab 87:489-499.
366. Garmendia Madariaga A, Santos Palacios S, Guillen-Grima F, Galofre JC 2014 The incidence and prevalence of thyroid dysfunction in Europe: a meta-analysis. J Clin Endocrinol Metab 99:923-931.
367. Schouten BJ, Brownlie BE, Frampton CM, Turner JG 2011 Subclinical thyrotoxicosis in an outpatient population-predictors of outcome. Clin Endocrinol(Oxf) 74: 257-261.
368. Lewis GF, Alessi CA, Imperial JG, Refetoff S 1991 Low serum free thyroxine index in ambulating elderly is due to a resetting of the threshold of thyrotropin feedback suppression. J Clin Endocrinol Metab 73:843-849.
369. Mariotti S, Barbesino G, Caturegli P, Bartalena L, Sansoni P, Fagnoni F, Monti D, Fagiolo U, Franceschi C, Pinchera A 1993 Complex alteration of thyroid function in healthy centenarians. J Clin Endocrinol Metab 77:1130-1134.
370. Parle JV, Franklyn JA, Cross KW, Jones SC, Sheppard MC 1991 Prevalence and follow-up of abnormal thyrotrophin (TSH) concentrations in the elderly in the United Kingdom. Clin Endocrinol(Oxf) 34:77-83.
371. Bjorndal MM, Sandmo Wilhelmsen K, Lu T, Jorde R 2008 Prevalence and causes of undiagnosed hyperthyroidismin an adult healthy population. The Tromso study. J Endocrinol Invest 31:856-860.
372. Meyerovitch J, Rotman-Pikielny P, Sherf M, Battat E, Levy Y, Surks MI 2007 Serum thyrotropin measurements in the community: five-year follow-up in a large network of primary care physicians. Arch Intern Med 167:1533-1538.
373. Sawin CT, Geller A, Kaplan MM, Bacharach P, Wilson PW, Hershman JM 1991 Low serum thyrotropin (thyroidstimulating hormone) in older persons without hyperthyroidism. Arch Intern Med 151:165-168.
374. Parle JV, Maisonneuve P, Sheppard MC, Boyle P, Franklyn JA 2001 Prediction of all-cause and cardiovascular mortality in elderly people from one low serum thyrotropin result: a 10-year cohort study. Lancet 358: 861-865.
375. Vadiveloo T, Donnan PT, Cochrane L, Leese GP 2011 The Thyroid Epidemiology, Audit, and Research Study (TEARS): the natural history of endogenous subclinical hyperthyroidism. J Clin Endocrinol Metab 96:E1-8.
376. Rosario PW 2010 Natural history of subclinical hyperthyroidism in elderly patients with TSH between 0. 1 and 0. 4 mIU/l: a prospective study. Clin Endocrinol(Oxf) 72: 685-688.
377. Das G, Ojewuyi TA, Baglioni P, Geen J, Premawardhana LD, Okosieme OE 2012 Serum thyrotrophin at baseline predicts the natural course of subclinical hyperthyroidism. Clin Endocrinol(Oxf) 77:146-151.
378. Woeber KA 2005 Observations concerning the natural history of subclinical hyperthyroidism. Thyroid 15:687-691.
379. Gussekloo J, van Exel E, de Craen AJ, Meinders AE, Frolich M, Westendorp RG 2004 Thyroid status, disability and cognitive function, and survival in old age. JAMA 292:2591-2599.
380. Ceresini G, Ceda GP, Lauretani F, Maggio M, Usberti E, Marina M, Bandinelli S, Guralnik JM, Valenti G, Ferrucci L 2013 Thyroid status and 6-year mortality in elderly people living in a mildly iodine-deficient area: the aging in the Chianti Area Study. J Am Geriatr Soc 61:868-874.
381. Selmer C, Olesen JB, Hansen ML, von Kappelgaard LM, Madsen JC, Hansen PR, Pedersen OD, Faber J, Torp-Pedersen C, Gislason GH 2014 Subclinical and overt thyroid dysfunction and risk of all-cause mortality and cardiovascular events: a large population study. J Clin Endocrinol Metab 99:2372-2382.
382. van de Ven AC, Netea-Maier RT, de Vegt F, Ross HA, Sweep FC, Kiemeney LA, Smit JW, Hermus AR, den Heijer M 2014 Associations between thyroid function and mortality: the influence of age. Eur J Endocrinol 171: 183-191.
383. Nanchen D, Gussekloo J, Westendorp RG, Stott DJ, Jukema JW, Trompet S, Ford I, Welsh P, Sattar N, Macfarlane PW, Mooijaart SP, Rodondi N, de Craen AJ, PROSPER Group 2012 Subclinical thyroid dysfunction and the risk of heart failure in older persons at high cardiovascular risk. J Clin Endocrinol Metab 97:852-861.
384. Cappola AR, Fried LP, Arnold AM, Danese MD, Kuller LH, Burke GL, Tracy RP, Ladenson PW 2006 Thyroid status, cardiovascular risk, and mortality in older adults. JAMA 295:1033-1041.
385. Walsh JP, Bremner AP, Bulsara MK, O'Leary P, Leedman PJ, Feddema P, Michelangeli V 2006 Subclinical thyroid dysfunction and blood pressure: a communitybased study. Clin Endocrinol (Oxf) 65:486-491.
386. Waring AC, Harrison S, Samuels MH, Ensrud KE, Le-BLanc ES, Hoffman AR, Orwoll E, Fink HA, Barrett-Connor E, Bauer DC, Osteoporotic Fractures in Men (MrOS) Study 2012 Thyroid function and mortality in older men: a prospective study. J Clin Endocrinol Metab 97:862-870.
387. Boekholdt SM, Titan SM, Wiersinga WM, Chatterjee K, Basart DC, Luben R, Wareham NJ, Khaw KT 2010 Initial thyroid status and cardiovascular risk factors: the EPICNorfolk prospective population study. Clin Endocrinol(Oxf) 72:404-410.
388. Collet TH, Gussekloo J, Bauer DC, den Elzen WP, Cappola AR, Balmer P, Iervasi G, Asvold BO, Sgarbi JA, Volzke H, Gencer B, Maciel RM, Molinaro S, Bremner A, Luben RN, Maisonneuve P, Cornuz J, Newman AB, Khaw KT, Westendorp RG, Franklyn JA, Vittinghoff E, Walsh JP, Rodondi N, Thyroid Studies Collaboration 2012 Subclinical hyperthyroidism and the risk of coronary heart disease and mortality. Arch Intern Med 172: 799-809.
389. Asvold BO, Bjoro T, Platou C, Vatten LJ 2012 Thyroid function and the risk of coronary heart disease: 12-year follow-up of the HUNT study in Norway. Clin Endocrinol( Oxf) 77:911-917.
390. Yang LB, Jiang DQ, Qi WB, Zhang T, Feng YL, Gao L, Zhao J 2012 Subclinical hyperthyroidism and the risk of cardiovascular events and all-cause mortality: an updated meta-analysis of cohort studies. Eur J Endocrinol 167: 75-84.
391. Vadiveloo T, Donnan PT, Cochrane L, Leese GP 2011 The Thyroid Epidemiology, Audit, and Research Study (TEARS): morbidity in patients with endogenous subclinical hyperthyroidism. J Clin Endocrinol Metab 96: 1344-1351.
392. Gencer B, Collet TH, Virgini V, Bauer DC, Gussekloo J, Cappola AR, Nanchen D, den Elzen WP, Balmer P, Luben RN, Iacoviello M, Triggiani V, Cornuz J, Newman AB, Khaw KT, Jukema JW, Westendorp RG, Vittinghoff E, Aujesky D, Rodondi N, Thyroid Studies Collaboration 2012 Subclinical thyroid dysfunction and the risk of heart failure events: an individual participant data analysis from 6 prospective cohorts. Circulation 126:1040-1049.
393. Sgarbi JA, Villaca FG, Garbeline B, Villar HE, Romaldini JH 2003 The effects of early antithyroid therapy for endogenous subclinical hyperthyroidism in clinical and heart abnormalities. J Clin Endocrinol Metab 88:1672-1677.
394. Faber J, Wiinberg N, Schifter S, Mehlsen J 2001 Haemodynamic changes following treatment of subclinical and overt hyperthyroidism. Eur J Endocrinol 145:391-396.
395. Abdulrahman RM, Delgado V, Ng AC, Ewe SH, Bertini M, Holman ER, Hovens GC, Pereira AM, Romijn JA, Bax JJ, Smit JW 2010 Abnormal cardiac contractility in longterm exogenous subclinical hyperthyroid patients as demonstrated by two-dimensional echocardiography speckle tracking imaging. Eur J Endocrinol 163:435-441.
396. Kaminski G, Michalkiewicz D, Makowski K, Podgajny Z, Szalus N, Ruchala M, Szczepanek E, Gielerak G 2011 Prospective echocardiographic evaluation of patients with endogenous subclinical hyperthyroidism and after restoring euthyroidism. Clin Endocrinol(Oxf) 74:501-507.
397. Rezzonico J, Niepomniszcze H, Rezzonico M, Pusiol E, Alberto M, Brenta G 2011 The association of insulin resistance with subclinical thyrotoxicosis. Thyroid 21: 945-949.
398. Maratou E, Hadjidakis DJ, Peppa M, Alevizaki M, Tsegka K, Lambadiari V, Mitrou P, Boutati E, Kollias A, Economopoulos T, Raptis SA, Dimitriadis G 2010 Studies of insulin resistance in patients with clinical and subclinical hyperthyroidism. Eur J Endocrinol 163:625-630.
399. Sawin CT, Geller A, Wolf PA, Belanger AJ, Baker E, Bacharach P, Wilson PW, Benjamin EJ, D'Agostino RB 1994 Low serum thyrotropin concentrations as a risk factor for atrial fibrillation in older persons. N Engl J Med 331:1249-1252.
400. Gammage MD, Parle JV, Holder RL, Roberts LM, Hobbs FD, Wilson S, Sheppard MC, Franklyn JA 2007 Association between serum free thyroxine concentration and atrial fibrillation. Arch Intern Med 167:928-934.
401. Selmer C, Olesen JB, Hansen ML, Lindhardsen J, Olsen AM, Madsen JC, Faber J, Hansen PR, Pedersen OD, Torp-Pedersen C, Gislason GH 2012 The spectrum of thyroid disease and risk of new onset atrial fibrillation: a large population cohort study. BMJ 345:e7895.
402. Schultz M, Kistorp C, Raymond I, Dimsits J, Tuxen C, Hildebrandt P, Faber J 2011 Cardiovascular events in thyroid disease: a population based, prospective study. Horm Metab Res 43:653-659.
403. Chaker L, Baumgartner C, Ikram MA, Dehghan A, Medici M, Visser WE, Hofman A, Rodondi N, Peeters RP, Franco OH 2014 Subclinical thyroid dysfunction and the risk of stroke: a systematic review and meta-analysis. Eur J Epidemiol 29:791-800.
404. Maor E, Kivity S, Kopel E, Segev S, Sidi Y, Goldenberg I, Olchovsky D 2013 Differences in heart rate profile during exercise among subjects with subclinical thyroid disease. Thyroid 23:1226-1232.
405. Kaminski G, Makowski K, Michalkiewicz D, Kowal J, Ruchala M, Szczepanek E, Gielerak G 2012 The influence of subclinical hyperthyroidism on blood pressure, heart rate variability, and prevalence of arrhythmias. Thyroid 22:454-460.
406. Cooper DS, Biondi B 2012 Subclinical thyroid disease. Lancet 379:1142-1154.
407. Abrahamsen B, Jorgensen HL, Laulund AS, Nybo M, Brix TH, Hegedus L 2014 Low serum thyrotropin level and duration of suppression as a predictor of major osteoporotic fractures-the OPENTHYRO register cohort. J Bone Miner Res 29:2040-2050.
408. Bauer DC, Ettinger B, Nevitt MC, Stone KL, Study of Osteoporotic Fractures Research Group 2001 Risk for fracture in women with low serum levels of thyroidstimulating hormone. Ann. Intern. Med. 134:561-568.
409. Lee JS, Buzkova P, Fink HA, Vu J, Carbone L, Chen Z, Cauley J, Bauer DC, Cappola AR, Robbins J 2010 Subclinical thyroid dysfunction and incident hip fracture in older adults. Arch Intern Med 170:1876-1883.
410. Svare A, Nilsen TI, Asvold BO, Forsmo S, Schei B, Bjoro T, Langhammer A 2013 Does thyroid function influence fracture risk? Prospective data from the HUNT2 study, Norway. Eur J Endocrinol 169:845-852.
411. Garin MC, Arnold AM, Lee JS, Robbins J, Cappola AR 2014 Subclinical thyroid dysfunction and hip fracture and bone mineral density in older adults: the cardiovascular health study. J Clin Endocrinol Metab 99:2657-2664.
412. Waring AC, Harrison S, Fink HA, Samuels MH, Cawthon PM, Zmuda JM, Orwoll ES, Bauer DC, Osteoporotic Fractures in Men (MrOS) Study 2013A prospective study of thyroid function, bone loss, and fractures in older men: the MrOS study. J Bone Miner Res 28:472-479.
413. Blum MR, Bauer DC, Collet TH, Fink HA, Cappola AR, da Costa BR, Wirth CD, Peeters RP, Asvold BO, den Elzen WP, Luben RN, Imaizumi M, Bremner AP, Gogakos A, Eastell R, Kearney PM, Strotmeyer ES, Wallace ER, Hoff M, Ceresini G, Rivadeneira F, Uitterlinden AG, Stott DJ, Westendorp RG, Khaw KT, Langhammer A, Ferrucci L, Gussekloo J, Williams GR, Walsh JP, Juni P, Aujesky D, Rodondi N, Thyroid Studies Collaboration 2015 Subclinical thyroid dysfunction and fracture risk: a meta-analysis. JAMA 313:2055-2065.
414. Mudde AH, Houben AJ, Nieuwenhuijzen Kruseman AC 1994 Bone metabolism during anti-thyroid drug treatment of endogenous subclinical hyperthyroidism. Clin Endocrinol (Oxf) 41:421-424.
415. Faber J, Jensen IW, Petersen L, Nygaard B, Hegedus L, Siersbaek-Nielsen K 1998 Normalization of serum thyrotrophin by means of radioiodine treatment in subclinical hyperthyroidism: effect on bone loss in postmenopausal women. Clin Endocrinol (Oxf) 48:285-290.
416. Greenlund LJ, Nair KS, Brennan MD 2008 Changes in body composition in women following treatment of overt and subclinical hyperthyroidism. Endocr Pract 14:973-978.
417. Rosario PW 2013 Radioiodine therapy in elderly patients with subclinical hyperthyroidism due to non-voluminous nodular goiter and its effect on bone metabolism. Arq Bras Endocrinol Metabol 57:144-147.
418. Gan EH, Pearce SH 2012 Clinical review: the thyroid in mind: cognitive function and low thyrotropin in older people. J Clin Endocrinol Metab 97:3438-3449.
419. Wijsman LW, de Craen AJ, Trompet S, Gussekloo J, Stott DJ, Rodondi N, Welsh P, Jukema JW, Westendorp RG, Mooijaart SP 2013 Subclinical thyroid dysfunction and cognitive decline in old age. PLoS One 8:e59199.
420. Formiga F, Ferrer A, Padros G, Contra A, Corbella X, Pujol R, Octabaix Study Group 2013 Thyroid status and functional and cognitive status at baseline and survival after 3 years of follow-up: the OCTABAIX study. Eur J Endocrinol 170:69-75.
421. Roberts LM, Pattison H, Roalfe A, Franklyn J, Wilson S, Hobbs FD, Parle JV 2006 Is subclinical thyroid dysfunction in the elderly associated with depression or cognitive dysfunction? Ann Intern Med 145:573-581.
422. Almeida OP, Alfonso H, Flicker L, Hankey G, Chubb SA, Yeap BB 2011 Thyroid hormones and depression: the Health in Men study. Am J Geriatr Psychiatry 19: 763-770.
423. de Jongh RT, Lips P, van Schoor NM, Rijs KJ, Deeg DJ, Comijs HC, Kramer MH, Vandenbroucke JP, Dekkers OM 2011 Endogenous subclinical thyroid disorders, physical and cognitive function, depression, and mortality in older individuals. Eur J Endocrinol 165:545-554.
424. Virgini VS, Wijsman LW, Rodondi N, Bauer DC, Kearney PM, Gussekloo J, den Elzen WP, Jukema JW, Westendorp RG, Ford I, Stott DJ, Mooijaart SP, PROSPER Study Group 2014 Subclinical thyroid dysfunction and functional capacity among elderly. Thyroid 24:208-214.
425. Ceresini G, Ceda GP, Lauretani F, Maggio M, Bandinelli S, Guralnik JM, Cappola AR, Usberti E, Morganti S, Valenti G, Ferrucci L 2011 Mild thyroid hormone excess is associated with a decreased physical function in elderly men. Aging Male 14:213-219.
426. Brennan MD, Powell C, Kaufman KR, Sun PC, Bahn RS, Nair KS 2006 The impact of overt and subclinical hyperthyroidism on skeletal muscle. Thyroid 16:375-380.
427. Surks MI, Ortiz E, Daniels GH, Sawin CT, Col NF, Cobin RH, Franklyn JA, Hershman JM, Burman KD, Denke MA, Gorman C, Cooper RS, Weissman NJ 2004 Sub-clinical thyroid disease: scientific review and guidelines for diagnosis and management. JAMA 291:228-238.
428. Biondi B, Bartalena L, Cooper DS, Hegedus L, Laurberg P, Kahaly GJ 2015 The 2015 European Thyroid Association Guidelines on Diagnosis and Treatment of Endogenous Subclinical Hyperthyroidism. Eur Thyroid J 4:149-163.
429. Haentjens P, Van Meerhaeghe A, Poppe K, Velkeniers B 2008 Subclinical thyroid dysfunction and mortality: an estimate of relative and absolute excess all-cause mortality based on time-to-event data from cohort studies. Eur J Endocrinol 159:329-341.
430. Biondi B, Palmieri EA, Fazio S, Cosco C, Nocera M, Sacca L, Filetti S, Lombardi G, Perticone F 2000 Endogenous subclinical hyperthyroidism affects quality of life and cardiac morphology and function in young and middle-aged patients. J Clin Endocrinol Metab 85:4701-4705.
431. Cooper DS, Laurberg P 2013 Hyperthyroidism in pregnancy. Lancet Diabetes Endocrinol. 1:238-249.
432. Carle A, Pedersen IB, Knudsen N, Perrild H, Ovesen L, Rasmussen LB, Laurberg P 2011 Epidemiology of subtypes of hyperthyroidism in Denmark: a population-based study. Eur JEndocrinol 164:801-809.
433. Lo JC, Rivkees SA, Chandra M, Gonzalez JR, Korelitz JJ, Kuzniewicz MW 2015 Gestational thyrotoxicosis, antithyroid drug use and neonatal outcomes within an integrated healthcare delivery system. Thyroid 25:698-705.
434. Andersen SL, Olsen J, Laurberg P 2016 Maternal thyroid disease in the Danish National Birth Cohort: prevalence and risk factors. Eur J Endocrinol 174:203-212.
435. Burrow GN, Fisher DA, Larsen PR 1994 Maternal and fetal thyroid function. N Engl J Med 331:1072-1078.
436. Glinoer D 1997 The regulation of thyroid function in pregnancy: pathways of endocrine adaptation from physiology to pathology. Endocr Rev 18:404-433.
437. Dashe JS, Casey BM, Wells CE, McIntire DD, Byrd EW, Leveno KJ, Cunningham FG 2005 Thyroid-stimulating hormone in singleton and twin pregnancy: importance of gestational age-specific reference ranges. Obstet Gynecol 106:753-757.
438. Lambert-Messerlian G, McClain M, Haddow JE, Palomaki GE, Canick JA, Cleary-Goldman J, Malone FD, Porter TF, Nyberg DA, Bernstein P, D'Alton ME, FaSTER Research Consortium 2008 First-and secondtrimester thyroid hormone reference data in pregnant women: a FaSTER (First-and Second-Trimester Evaluation of Risk for aneuploidy) Research Consortium study. Am J Obstet Gynecol 199:62. e1-62. e6.
439. Li C, Shan Z, Mao J, Wang W, Xie X, Zhou W, Li C, Xu B, Bi L, Meng T, Du J, Zhang S, Gao Z, Zhang X, Yang L, Fan C, Teng W 2014 Assessment of thyroid function during first-trimester pregnancy: what is the rational upper limit of serum TSH during the first trimester in Chinese pregnant women? J Clin Endocrinol Metab 99:73-79.
440. Hershman JM 2008 The role of human chorionic gonadotropin as a thyroid stimulator in normal pregnancy. J Clin Endocrinol Metab 93:3305-3306.
441. Soldin OP, Tractenberg RE, Hollowell JG, Jonklaas J, Janicic N, Soldin SJ 2004 Trimester-specific changes in maternal thyroid hormone, thyrotropin, and thyroglobulin concentrations during gestation: trends and associations across trimesters in iodine sufficiency. Thyroid 14:1084-1090.
442. Mandel SJ, Spencer CA, Hollowell JG 2005 Are detection and treatment of thyroid insufficiency in pregnancy feasible? Thyroid 15:44-53.
443. Weeke J, Dybkjaer L, Granlie K, Eskjaer Jensen S, Kjaerulff E, Laurberg P, Magnusson B 1982A longitudinal study of serum TSH, and total and free iodothyronines during normal pregnancy. Acta Endocrinol (Copenh) 101: 531-537.
444. Laurberg P, Bournaud C, Karmisholt J, Orgiazzi J 2009 Management of Graves' hyperthyroidism in pregnancy: focus on both maternal and foetal thyroid function, and caution against surgical thyroidectomy in pregnancy. Eur J Endocrinol 160:1-8.
445. Nelson JC, Wang R, Asher DT, Wilcox RB 2004 The nature of analogue-based free thyroxine estimates. Thyroid 14:1030-1036.
446. Lee RH, Spencer CA, Mestman JH, Miller EA, Petrovic I, Braverman LE, Goodwin TM 2009 Free T4 immunoassays are flawed during pregnancy. Am J Obstet Gynecol 200:260. e1-260. e6.
447. Gong Y, Hoffman BR 2008 Free thyroxine reference interval in each trimester of pregnancy determined with the Roche Modular E-170 electrochemiluminescent immunoassay. Clin Biochem 41:902-906.
448. Silvio R, Swapp KJ, La'ulu SL, Hansen-Suchy K, Roberts WL 2009 Method specific second-trimester reference intervals for thyroid-stimulating hormone and free thyroxine. Clin Biochem 42:750-753.
449. Casey BM, Dashe JS, Wells CE, McIntire DD, Leveno KJ, Cunningham FG 2006 Subclinical hyperthyroidism and pregnancy outcomes. Obstet Gynecol 107:337-341.
450. Lip GY, Beevers M, Churchill D, Shaffer LM, Beevers DG 1997 Effect of atenolol on birth weight. Am J Cardiol 79:1436-1438.
451. Nakhai-Pour HR, Rey E, Berard A 2010 Antihypertensive medication use during pregnancy and the risk of major congenital malformations or small-for-gestational-age newborns. Birth Defects Res B Dev Reprod Toxicol 89: 147-154.
452. Davis LE, Lucas MJ, Hankins GD, Roark ML, Cunningham FG 1989 Thyrotoxicosis complicating pregnancy. Am J Obstet Gynecol 160:63-70.
453. Millar LK, Wing DA, Leung AS, Koonings PP, Montoro MN, Mestman JH 1994 Low birth weight and preeclampsia in pregnancies complicated by hyperthyroidism. Obstet Gynecol 84:946-949.
454. Kriplani A, Buckshee K, Bhargava VL, Takkar D, Ammini AC 1994 Maternal and perinatal outcome in thyrotoxicosis complicating pregnancy. Eur J Obstet Gynecol Reprod Biol 54:159-163.
455. Vos XG, Smit N, Endert E, Tijssen JG, Wiersinga WM 2008 Frequency and characteristics of TBII-seronegative patients in a population with untreated Graves' hyperthyroidism: a prospective study. Clin Endocrinol (Oxf) 69:311-317.
456. Andersen SL, Olsen J, Carle A, Laurberg P 2015 Hyperthyroidism incidence fluctuates widely in and around pregnancy and is at variance with some other autoimmune diseases: a Danish population-based study. J Clin Endocrinol Metab 100:1164-1171.
457. Amino N, Tanizawa O, Mori H, Iwatani Y, Yamada T, Kurachi K, Kumahara Y, Miyai K 1982 Aggravation of thyrotoxicosis in early pregnancy and after delivery in Graves' disease. J Clin Endocrinol Metab 55:108-112.
458. Momotani N, Noh J, Oyanagi H, Ishikawa N, Ito K 1986 Antithyroid drug therapy for Graves' disease during pregnancy. Optimal regimen for fetal thyroid status. N Engl J Med 315:24-28.
459. Amino N, Tada H, Hidaka Y 1999 Postpartum autoimmune thyroid syndrome: a model of aggravation of autoimmune disease. Thyroid 9:705-713.
460. Mortimer RH, Galligan JP, Cannell GR, Addison RS, Roberts MS 1996 Maternal to fetal thyroxine transmission in the human term placenta is limited by inner ring deiodination. J Clin Endocrinol Metab 81:2247-2249.
461. Milham S, Elledge W 1972 Maternal methimazole and congenital defects in children. Teratology 5:125-126.
462. Yoshihara A, Noh J, Yamaguchi T, Ohye H, Sato S, Sekiya K, Kosuga Y, Suzuki M, Matsumoto M, Kunii Y, Watanabe N, Mukasa K, Ito K, Ito K 2012 Treatment of Graves' disease with antithyroid drugs in the first trimester of pregnancy and the prevalence of congenital malformation. J Clin Endocrinol Metab 97:2396-2403.
463. Andersen SL, Olsen J, Wu CS, Laurberg P 2013 Birth defects after early pregnancy use of antithyroid drugs: a Danish nationwide study. J Clin Endocrinol Metab 98:4373-4381.
464. Foulds N, Walpole I, Elmslie F, Mansour S 2005 Carbimazole embryopathy: an emerging phenotype. Am J Med Genet A 132A:130-135.
465. Korelitz JJ, McNally DL, Masters MN, Li SX, Xu Y, Rivkees SA 2013 Prevalence of thyrotoxicosis, antithyroid medication use, and complications among pregnant women in the United States. Thyroid 23:758-765.
466. Andersen SL, Olsen J, Wu CS, Laurberg P 2014 Severity of birth defects after propylthiouracil exposure in early pregnancy. Thyroid 24:1533-1540.
467. Clementi M, Di Gianantonio E, Cassina M, Leoncini E, Botto LD, Mastroiacovo P, SAFE-Med Study Group 2010 Treatment of hyperthyroidism in pregnancy and birth defects. J Clin Endocrinol Metab 95:E337-41.
468. Moore KL, Persaud TVN, Torchia MG 2013 Human birth defects. The Developing Human: Clinically Oriented Embryology. 9th edition. Saunders/Elsevier, Philadelphia, PA, pp 471-501.
469. Laurberg P, Andersen SL 2014 Therapy of endocrine disease: antithyroid drug use in early pregnancy and birth defects: time windows of relative safety and high risk? Eur J Endocrinol 171:R13-20.
470. FDA 2009 U. S. Food and Drug Administration information for healthcare professionals-propylthiouracil-induced liver failure. Available at: www. fda. gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm209023. htm (accessed January 19, 2016).
471. Moser M, Brown CM, Rose CH, Garovic VD 2012 Hypertension in pregnancy: is it time for a new approach to treatment? J Hypertens 30:1092-1100.
472. Yoshioka W, Miyauchi A, Ito M, Kudo T, Tamai H, Nishihara E, Kihara M, Miya A, Amino N 2015 Kinetic analyses of changes in serum TSH receptor antibody values after total thyroidectomy in patients with Graves' disease. Endocr J
473. Laurberg P, Krejbjerg A, Andersen SL 2014 Relapse following antithyroid drug therapy for Graves' hyperthyroidism. Curr Opin Endocrinol Diabetes Obes 21: 415-421.
474. Gnoth C, Godehardt D, Godehardt E, Frank-Herrmann P, Freundl G 2003 Time to pregnancy: results of the German prospective study and impact on the management of infertility. Hum Reprod 18:1959-1966.
475. Mohlin E, Filipsson Nystrom H, Eliasson M 2014 Longterm prognosis after medical treatment of Graves' disease in a northern Swedish population 2000-2010. Eur J Endocrinol 170:419-427.
476. Yoshihara A, Noh JY, Watanabe N, Mukasa K, Ohye H, Suzuki M, Matsumoto M, Kunii Y, Suzuki N, Kameda T, Iwaku K, Kobayashi S, Sugino K, Ito K 2015 Substituting potassium iodide for methimazole as the treatment for Graves' disease during the first trimester may reduce the incidence of congenital anomalies: a retrospective study at a single medical institution in Japan. Thyroid 25: 1155-1161.
477. Anselmo J, Cao D, Karrison T, Weiss RE, Refetoff S 2004 Fetal loss associated with excess thyroid hormone exposure. JAMA 292:691-695.
478. Andersen SL, Olsen J, Wu CS, Laurberg P 2014 Spontaneous abortion, stillbirth and hyperthyroidism: a danish population-based study. Eur Thyroid J 3:164-172.
479. Molitch ME 2015 Endocrinology in pregnancy: management of the pregnant patient with a prolactinoma. Eur J Endocrinol 172:R205-13.
480. Kallner G, Vitols S, Ljunggren JG 1996 Comparison of standardized initial doses of two antithyroid drugs in the treatment of Graves' disease. J Intern Med 239:525-529.
481. Homsanit M, Sriussadaporn S, Vannasaeng S, Peerapatdit T, Nitiyanant W, Vichayanrat A 2001 Efficacy of single daily dosage of methimazole vs. propylthiouracil in the induction of euthyroidism. Clin Endocrinol (Oxf) 54:385-390.
482. He CT, Hsieh AT, Pei D, Hung YJ, Wu LY, Yang TC, Lian WC, Huang WS, Kuo SW 2004 Comparison of single daily dose of methimazole and propylthiouracil in the treatment of Graves' hyperthyroidism. Clin Endocrinol (Oxf) 60:676-681.
483. Momotani N, Hisaoka T, Noh J, Ishikawa N, Ito K 1992 Effects of iodine on thyroid status of fetus versus mother in treatment of Graves' disease complicated by pregnancy. J Clin Endocrinol Metab 75:738-744.
484. Means J, H. 1948 The response to iodine and to antithyroid drugs in Graves' disease. The Thyroid and Its Diseases. 2nd edition. Lippincott, Philadelphia, PA, pp 341-374.
485. Wolff J 1998 Perchlorate and the thyroid gland. Pharmacol Rev 50:89-105.
486. EFSA CONTAM Panel (EFSA Panel on Contaminants in the Food Chain) 2014 Scientific opinion on the risks to public health related to the presence of perchlorate in food, in particular fruits and vegetables. EFSA J 12:3869 (www. efsa. europa. eu/efsajournal/en/pub/3869. htm).
487. Solomon BL, Wartofsky L, Burman KD 1993 Adjunctive cholestyramine therapy for thyrotoxicosis. Clin Endocrinol (Oxf) 38:39-43.
488. Mercado M, Mendoza-Zubieta V, Bautista-Osorio R, Espinoza-de los Monteros AL 1996 Treatment of hyperthyroidism with a combination of methimazole and cholestyramine. J Clin Endocrinol Metab 81:3191-3193.
489. Diav-Citrin O, Shechtman S, Tahover E, Finkel-Pekarsky V, Arnon J, Kennedy D, Erebara A, Einarson A, Ornoy A 2014 Pregnancy outcome following in utero exposure to lithium: a prospective, comparative, observational study. Am J Psychiatry 171:785-794.
490. Bliddal S, Rasmussen AK, Sundberg K, Feldt-Rasmussen U 2013 Careful assessment of maternal thyroid function can prevent cases of fetal goitrous hypothyroidism. Fetal Diagn Ther 34:66-67.
491. Momotani N, Noh JY, Ishikawa N, Ito K 1997 Effects of propylthiouracil and methimazole on fetal thyroid status in mothers with Graves' hyperthyroidism. J Clin Endocrinol Metab 82:3633-3636.
492. Berta E, Samson L, Lenkey A, Erdei A, Cseke B, Jenei K, Major T, Jakab A, Jenei Z, Paragh G, Nagy EV, Bodor M 2010 Evaluation of the thyroid function of healthy pregnant women by five different hormone assays. Pharmazie 65:436-439.
493. Laurberg P, Vestergaard H, Nielsen S, Christensen SE, Seefeldt T, Helleberg K, Pedersen KM 2007 Sources of circulating 3, 5, 3-triiodothyronine in hyperthyroidism estimated after blocking of type 1 and type 2 iodothyronine deiodinases. J Clin Endocrinol Metab 92:2149-2156.
494. Laurberg P 1984 Mechanisms governing the relative proportions of thyroxine and 3, 5, 3-triiodothyronine in thyroid secretion. Metabolism 33:379-392.
495. Laurberg P, Nygaard B, Glinoer D, Grussendorf M, Orgiazzi J 1998 Guidelines for TSH-receptor antibody measurements in pregnancy: results of an evidence-based symposium organized by the European Thyroid Association. Eur J Endocrinol 139:584-586.
496. Senior B, Chernoff HL 1971 Iodide goiter in the newborn. Pediatrics 47:510-515.
497. Geelhoed GW 1983 Surgery of the endocrine glands in pregnancy. Clin Obstet Gynecol 26:865-889.
498. Seeley BL, Burrow GN 1991 Thyrotoxicosis in pregnancy. Endocrinologist 1:409-417.
499. Chan GW, Mandel SJ 2007 Therapy insight: management of Graves' disease during pregnancy. Nat Clin Pract Endocrinol Metab 3:470-478.
500. Zakarija M, McKenzie JM 1983 Pregnancy-associated changes in the thyroid-stimulating antibody of Graves' disease and the relationship to neonatal hyperthyroidism. J Clin Endocrinol Metab 57:1036-1040.
501. Polak M, Le Gac I, Vuillard E, Guibourdenche J, Leger J, Toubert ME, Madec AM, Oury JF, Czernichow P, Luton D 2004 Fetal and neonatal thyroid function in relation to maternal Graves' disease. Best Pract Res Clin Endocrinol Metab 18:289-302.
502. Donnelly MA, Wood C, Casey B, Hobbins J, Barbour LA 2015 Early severe fetal Graves disease in a mother after thyroid ablation and thyroidectomy. Obstet Gynecol 125:1059-1062.
503. Mortimer RH, Tyack SA, Galligan JP, Perry-Keene DA, Tan YM 1990 Graves' disease in pregnancy: TSH receptor binding inhibiting immunoglobulins and maternal and neonatal thyroid function. Clin Endocrinol (Oxf) 32:141-152.
504. Abeillon-du Payrat J, Chikh K, Bossard N, Bretones P, Gaucherand P, Claris O, Charrie A, Raverot V, Orgiazzi J, Borson-Chazot F, Bournaud C 2014 Predictive value of maternal second-generation thyroid-binding inhibitory immunoglobulin assay for neonatal autoimmune hyperthyroidism. Eur J Endocrinol 171:451-460.
505. Roti E, Uberti E 2002 Post-partum thyroiditis-a clinical update. Eur J Endocrinol 146:275-279.
506. Stagnaro-Green A 2002 Clinical review 152: Postpartum thyroiditis. J Clin Endocrinol Metab 87:4042-4047.
507. Kuijpens JL, Pop VJ, Vader HL, Drexhage HA, Wiersinga WM 1998 Prediction of post partum thyroid dysfunction: can it be improved? Eur J Endocrinol 139:36-43.
508. Ide A, Amino N, Kang S, Yoshioka W, Kudo T, Nishihara E, Ito M, Nakamura H, Miyauchi A 2014 Differentiation of postpartum Graves' thyrotoxicosis from postpartum destructive thyrotoxicosis using antithyrotropin receptor antibodies and thyroid blood flow. Thyroid 24:1027-1031.
509. Tagami T, Hagiwara H, Kimura T, Usui T, Shimatsu A, Naruse M 2007 The incidence of gestational hyperthyroidism and postpartum thyroiditis in treated patients with Graves' disease. Thyroid 17:767-772.
510. Stabin MG, Breitz HB 2000 Breast milk excretion of radiopharmaceuticals: mechanisms, findings, and radiation dosimetry. J Nucl Med 41:863-873.
511. Gorman CA 1999 Radioiodine and pregnancy. Thyroid 9:721-726.
512. Ota H, Amino N, Morita S, Kobayashi K, Kubota S, Fukata S, Kamiyama N, Miyauchi A 2007 Quantitative measurement of thyroid blood flow for differentiation of painless thyroiditis from Graves' disease. Clin Endocrinol (Oxf) 67:41-45.
513. Hiraiwa T, Tsujimoto N, Tanimoto K, Terasaki J, Amino N, Hanafusa T 2013 Use of color Doppler ultrasonography to measure thyroid blood flow and differentiate Graves' disease from painless thyroiditis. Eur Thyroid J 2: 120-126.
514. Davanzo R, Rubert L, Oretti C 2008 Meta-variability of advice on drugs in the breastfeeding mother: the example of beta-blockers. Arch Dis Child Fetal Neonatal Ed 93: F249-50.
515. Eidelman AI, Schimmel MS 1995 Drugs and breast milk. Pediatrics 95:956-7; author reply 957-8.
516. Bahn RS 2010 Graves' ophthalmopathy. N Engl J Med 362:726-738.
517. Laurberg P, Berman DC, Bulow Pedersen I, Andersen S, Carle A 2012 Incidence and clinical presentation of moderate to severe Graves' orbitopathy in a Danish population before and after iodine fortification of salt. J Clin Endocrinol Metab 97:2325-2332.
518. Tanda ML, Piantanida E, Liparulo L, Veronesi G, Lai A, Sassi L, Pariani N, Gallo D, Azzolini C, Ferrario M, Bartalena L 2013 Prevalence and natural history of Graves' orbitopathy in a large series of patients with newly diagnosed Graves' hyperthyroidism seen at a single center. J Clin Endocrinol Metab 98:1443-1449.
519. Marcocci C, Bartalena L, Bogazzi F, Panicucci M, Pinchera A 1989 Studies on the occurrence of ophthalmopathy in Graves' disease. Acta Endocrinol (Copenh) 120:473-478.
520. Jacobson DH, Gorman CA 1984 Endocrine ophthalmopathy: current ideas concerning etiology, pathogenesis, and treatment. Endocr Rev 5:200-220.
521. Perros P, Crombie AL, Kendall-Taylor P 1995 Natural history of thyroid associated ophthalmopathy. Clin Endocrinol (Oxf) 42:45-50.
522. Bartley GB 1994 The epidemiologic characteristics and clinical course of ophthalmopathy associated with autoimmune thyroid disease in Olmsted County, Minnesota. Trans Am. Ophthalmol Soc 92:477-588.
523. Mourits MP, Koornneef L, Wiersinga WM, Prummel MF, Berghout A, van der Gaag R 1989 Clinical criteria for the assessment of disease activity in Graves' ophthalmopathy: a novel approach. Br J Ophthalmol 73:639-644.
524. Mourits MP, Prummel MF, Wiersinga WM, Koornneef L 1997 Clinical activity score as a guide in the management of patients with Graves' ophthalmopathy. Clin Endocrinol (Oxf) 47:9-14.
525. Bartalena L, Baldeschi L, Dickinson AJ, Eckstein A, Kendall-Taylor P, Marcocci C, Mourits MP, Perros P, Boboridis K, Boschi A, Curro N, Daumerie C, Kahaly GJ, Krassas G, Lane CM, Lazarus JH, Marino M, Nardi M, Neoh C, Orgiazzi J, Pearce S, Pinchera A, Pitz S, Salvi M, Sivelli P, Stahl M, von Arx G, Wiersinga WM 2008 Consensus statement of the European group on Graves' orbitopathy (EUGOGO) on management of Graves' orbitopathy. Thyroid 18:333-346.
526. Abraham-Nordling M, Wallin G, Traisk F, Berg G, Calissendorff J, Hallengren B, Hedner P, Lantz M, Nystrom E, Asman P, Lundell G, Torring O, Thyroid Study Group of TT 96 2010 Thyroid-associated ophthalmopathy; quality of life follow-up of patients randomized to treatment with antithyroid drugs or radioiodine. Eur J Endocrinol 163:651-657.
527. Yeatts RP 2005 Quality of life in patients with Graves ophthalmopathy. Trans Am Ophthalmol Soc 103:368-411.
528. Fayers T, Dolman PJ 2011 Validity and reliability of the TED-QOL: a new three-item questionnaire to assess quality of life in thyroid eye disease. Br J Ophthalmol 95:1670-1674.
529. Terwee CB, Gerding MN, Dekker FW, Prummel MF, Wiersinga WM 1998 Development of a disease specific quality of life questionnaire for patients with Graves' ophthalmopathy: the GO-QOL. Br J Ophthalmol 82:773-779.
530. Jellema HM, Braaksma-Besselink Y, Limpens J, von Arx G, Wiersinga WM, Mourits MP 2015 Proposal of success criteria for strabismus surgery in patients with Graves' orbitopathy based on a systematic literature review. Acta Ophthalmol 93:601-609.
531. Bartalena L, Marcocci C, Bogazzi F, Manetti L, Tanda ML, Dell'Unto E, Bruno-Bossio G, Nardi M, Bartolomei MP, Lepri A, Rossi G, Martino E, Pinchera A 1998 Relation between therapy for hyperthyroidism and the course of Graves' ophthalmopathy. N Engl J Med 338:73-78.
532. Tallstedt L, Lundell G, Torring O, Wallin G, Ljunggren JG, Blomgren H, Taube A 1992 Occurrence of ophthalmopathy after treatment for Graves' hyperthyroidism. The Thyroid Study Group. N Engl J Med 326:1733-1738.
533. Eckstein AK, Plicht M, Lax H, Neuhauser M, Mann K, Lederbogen S, Heckmann C, Esser J, Morgenthaler NG 2006 Thyrotropin receptor autoantibodies are independent risk factors for Graves' ophthalmopathy and help to predict severity and outcome of the disease. J Clin Endocrinol Metab 91:3464-3470.
534. Tallstedt L, Lundell G, Blomgren H, Bring J 1994 Does early administration of thyroxine reduce the development of Graves' ophthalmopathy after radioiodine treatment? Eur J Endocrinol 130:494-497.
535. Prummel MF, Wiersinga WM, Mourits MP, Koornneef L, Berghout A, van der Gaag R 1990 Effect of abnormal thyroid function on the severity of Graves' ophthalmopathy. Arch Intern Med 150:1098-1101.
536. Perros P, Kendall-Taylor P, Neoh C, Frewin S, Dickinson J 2005A prospective study of the effects of radioiodine therapy for hyperthyroidism in patients with minimally active graves' ophthalmopathy. J Clin Endocrinol Metab 90:5321-5323.
537. Pfeilschifter J, Ziegler R 1996 Smoking and endocrine ophthalmopathy: impact of smoking severity and current vs lifetime cigarette consumption. Clin Endocrinol(Oxf) 45:477-481.
538. Eisenberg MJ, Filion KB, Yavin D, Belisle P, Mottillo S, Joseph L, Gervais A, O'Loughlin J, Paradis G, Rinfret S, Pilote L 2008 Pharmacotherapies for smoking cessation: a meta-analysis of randomized controlled trials. CMAJ 179: 135-144.
539. Fiore MC, Jaen CR 2008A clinical blueprint to accelerate the elimination of tobacco use. JAMA 299:2083-2085.
540. Watanabe N, Noh JY, Kozaki A, Iwaku K, Sekiya K, Kosuga Y, Matsumoto M, Suzuki M, Yoshihara A, Ohye H, Kobayashi S, Kunii Y, Mukasa K, Sugino K, Inoue T, Ito K 2015 Radioiodine-associated exacerbation of Graves' orbitopathy in the Japanese population: randomized prospective study. J Clin Endocrinol Metab 100: 2700-2708.
541. Sridama V, DeGroot LJ 1989 Treatment of Graves' disease and the course of ophthalmopathy. Am J Med 87:70-73.
542. Turcu AF, Kumar S, Neumann S, Coenen M, Iyer S, Chiriboga P, Gershengorn MC, Bahn RS 2013A small molecule antagonist inhibits thyrotropin receptor antibodyinduced orbital fibroblast functions involved in the pathogenesis of Graves ophthalmopathy. J Clin Endocrinol Metab 98:2153-2159.
543. Kumar S, Iyer S, Bauer H, Coenen M, Bahn RS 2012A stimulatory thyrotropin receptor antibody enhances hyaluronic acid synthesis in Graves' orbital fibroblasts: inhibition by an IGF-I receptor blocking antibody. J Clin Endocrinol Metab 97:1681-1687.
544. Lai A, Sassi L, Compri E, Marino F, Sivelli P, Piantanida E, Tanda ML, Bartalena L 2010 Lower dose prednisone prevents radioiodine-associated exacerbation of initially mild or absent Graves' orbitopathy: a retrospective cohort study. J Clin Endocrinol Metab 95:1333-1337.
545. Fernandez Sanchez JR, Rosell Pradas J, Carazo Martinez O, Torres Vela E, Escobar Jimenez F, Garbin Fuentes I, Vara Thorbeck R 1993 Graves' ophthalmopathy after subtotal thyroidectomy and radioiodine therapy. Br J Surg 80:1134-1136.
546. Jarhult J, Rudberg C, Larsson E, Selvander H, Sjovall K, Winsa B, Rastad J, Karlsson FA, TEO Study Group 2005 Graves' disease with moderate-severe endocrine ophthalmopathy-long term results of a prospective, randomized study of total or subtotal thyroid resection. Thyroid 15:1157-1164.
547. Domoslawski P, Lukienczuk T, Forkasiewicz Z, Balcerzak W, Bednarz W, Dawiskiba J, Krawczyk Z, Wojtczak B, Olewinski R, Podhorska-Okolow M 2007 Influence of total thyroidectomy on orbital opthalmopathy and levels of antithyroid antibodies in patients with Graves' disease. Polski Przeglad Chirurgiczny 79:303-312.
548. De Bellis A, Conzo G, Cennamo G, Pane E, Bellastella G, Colella C, Iacovo AD, Paglionico VA, Sinisi AA, Wall JR, Bizzarro A, Bellastella A 2012 Time course of Graves' ophthalmopathy after total thyroidectomy alone or followed by radioiodine therapy: a 2-year longitudinal study. Endocrine 41:320-326.
549. Laurberg P, Berman DC, Andersen S, Bulow Pedersen I 2011 Sustained control of Graves' hyperthyroidism during long-term low-dose antithyroid drug therapy of patients with severe Graves' orbitopathy. Thyroid 21:951-956.
550. Vannucchi G, Campi I, Covelli D, Dazzi D, Curro N, Simonetta S, Ratiglia R, Beck-Peccoz P, Salvi M 2009 Graves' orbitopathy activation after radioactive iodine therapy with and without steroid prophylaxis. J Clin Endocrinol Metab 94:3381-3386.
551. Martin FI, Tress BW, Colman PG, Deam DR 1993 Iodineinduced hyperthyroidism due to nonionic contrast radiography in the elderly. Am J Med 95:78-82.
552. Fradkin JE, Wolff J 1983 Iodide-induced thyrotoxicosis. Medicine (Baltimore) 62:1-20.
553. Alkhuja S, Pyram R, Odeyemi O 2013 In the eye of the storm: iodinated contrast medium induced thyroid storm presenting as cardiopulmonary arrest. Heart Lung 42:267-269.
554. Blum M, Kranjac T, Park CM, Engleman RM 1976 Thyroid storm after cardiac angiography with iodinated contrast medium. Occurrence in a patient with a previously euthyroid autonomous nodule of the thyroid. JAMA 235:2324-2325.
555. Shimura H, Takazawa K, Endo T, Tawata M, Onaya T 1990 T4-thyroid storm after CT-scan with iodinated contrast medium. J Endocrinol Invest 13:73-76.
556. Kobberling J, Hintze G, Becker HD 1985 Iodine-induced thyrotoxicosis-a case for subtotal thyroidectomy in severely ill patients. Klin Wochenschr 63:1-7.
557. Burgi H 2010 Iodine excess. Best Pract Res Clin Endocrinol Metab 24:107-115.
558. Lee SY, Rhee CM, Leung AM, Braverman LE, Brent GA, Pearce EN 2015A review: radiographic iodinated contrast media-induced thyroid dysfunction. J Clin Endocrinol Metab 100:376-383.
559. Roti E, Gardini E, Minelli R, Bianconi L, Salvi M, Gavaruzzi G, Braverman LE 1993 Effects of chronic iodine administration on thyroid status in euthyroid subjects previously treated with antithyroid drugs for Graves' hyperthyroidism. J Clin Endocrinol Metab 76:928-932.
560. Skare S, Frey HM 1980 Iodine induced thyrotoxicosis in apparently normal thyroid glands. Acta Endocrinol (Copenh) 94:332-336.
561. Laurberg P, Cerqueira C, Ovesen L, Rasmussen LB, Perrild H, Andersen S, Pedersen IB, Carle A 2010 Iodine intake as a determinant of thyroid disorders in populations. Best Pract Res. Clin Endocrinol Metab 24:13-27.
562. Conn JJ, Sebastian MJ, Deam D, Tam M, Martin FI 1996A prospective study of the effect of nonionic contrast media on thyroid function. Thyroid 6:107-110.
563. Kaneshige T, Arata N, Harada S, Ohashi T, Sato S, Umehara N, Saito T, Saito H, Murashima A, Sago H 2015 Changes in serum iodine concentration, urinary iodine excretion and thyroid function after hysterosalpingography using an oil-soluble iodinated contrast medium (lipiodol). J Clin Endocrinol Metab 100:E469-72.
564. Koroscil TM, Pelletier PR, Slauson JW, Hennessey J 1997 Short-term effects of coronary angiographic contrast agents on thyroid function. Endocr Pract 3:219-221.
565. Lee SY, Chang DL, He X, Pearce EN, Braverman LE, Leung AM 2015 Urinary iodine excretion and serum thyroid function in adults after iodinated contrast administration. Thyroid 25:471-477.
566. Hintze G, Blombach O, Fink H, Burkhardt U, Kobberling J 1999 Risk of iodine-induced thyrotoxicosis after coronary angiography: an investigation in 788 unselected subjects. Eur J Endocrinol 140:264-267.
567. Jarvis C, Simcox K, Tamatea JA, McAnulty K, Meyer-Rochow GY, Conaglen JV, Elston MS 2016A low incidence of iodine-induced hyperthyroidism following administration of iodinated contrast in an iodine-deficient region. Clin Endocrinol (Oxf) 84:558-563.
568. Marraccini P, Bianchi M, Bottoni A, Mazzarisi A, Coceani M, Molinaro S, Lorenzoni V, Landi P, Iervasi G 2013 Prevalence of thyroid dysfunction and effect of contrast medium on thyroid metabolism in cardiac patients undergoing coronary angiography. Acta Radiol 54:42-47.
569. Ozkan S, Oysu AS, Kayatas K, Demirtunc R, Eren M, Uslu H, Altuntas Y 2013 Thyroid functions after contrast agent administration for coronary angiography: a prospective observational study in euthyroid patients. Anadolu Kardiyol Derg 13:363-369.
570. Rhee CM, Bhan I, Alexander EK, Brunelli SM 2012 Association between iodinated contrast media exposure and incident hyperthyroidism and hypothyroidism. Arch Intern Med 172:153-159.
571. Taylor PN, Okosieme OE, Dayan CM, Lazarus JH 2013 Therapy of endocrine disease: impact of iodine supplementation in mild-to-moderate iodine deficiency: systematic review and meta-analysis. Eur J Endocrinol 170:R1-R15.
572. Mishra A, Pradhan PK, Gambhir S, Sabaretnam M, Gupta A, Babu S 2015 Preoperative contrast-enhanced computerized tomography should not delay radioiodine ablation in differentiated thyroid carcinoma patients. J Surg Res 193:731-737.
573. Basaria S, Cooper DS 2005 Amiodarone and the thyroid. Am J Med 118:706-714.
574. Bogazzi F, Tomisti L, Bartalena L, Aghini-Lombardi F, Martino E 2012 Amiodarone and the thyroid: a 2012 update. J Endocrinol Invest 35:340-348.
575. Iudica-Souza CB, Burch H 1999 Amiodarone-induced thryoid dysfunction. Endocrinologist 9:216-227.
576. Martino E, Safran M, Aghini-Lombardi F, Rajatanavin R, Lenziardi M, Fay M, Pacchiarotti A, Aronin N, Macchia E, Haffajee C 1984 Environmental iodine intake and thyroid dysfunction during chronic amiodarone therapy. Ann Intern Med 101:28-34.
577. Bickford CL, Spencer AP 2006 Adherence to the NASPE guideline for amiodarone monitoring at a medical university. J Manag Care Pharm 12:254-259.
578. Johnson SG, Canty K, Billups S, Schimmer J 2010 Adherence to amiodarone monitoring recommendations before and after implementation of a centralized pharmacy service: a cohort study. J Pharm Pract 23:536-539.
579. Brennan MD, Erickson DZ, Carney JA, Bahn RS 1995 Nongoitrous (type I) amiodarone-associated thyrotoxicosis: evidence of follicular disruption in vitro and in vivo. Thyroid 5:177-183.
580. Chiovato L, Martino E, Tonacchera M, Santini F, Lapi P, Mammoli C, Braverman LE, Pinchera A 1994 Studies on the in vitro cytotoxic effect of amiodarone. Endocrinology 134:2277-2282.
581. Di Matola T, D'Ascoli F, Fenzi G, Rossi G, Martino E, Bogazzi F, Vitale M 2000 Amiodarone induces cytochrome c release and apoptosis through an iodineindependent mechanism. J Clin Endocrinol Metab 85:4323-4330.
582. Mete O, Asa SL 2012 Images in endocrine pathology: thyrotoxicosis associated with destructive thyroiditis. Endocr Pathol 23:212-214.
583. Gotzsche LS, Boye N, Laurberg P, Andreasen F 1989 Rat heart thyroxine 5-deiodinase is sensitively depressed by amiodarone. J Cardiovasc Pharmacol 14:836-841.
584. Wong R, Cheung W, Stockigt JR, Topliss DJ 2003 Heterogeneity of amiodarone-induced thyrotoxicosis: evaluation of colour-flow Doppler sonography in predicting therapeutic response. Intern Med J 33:420-426.
585. Ahmed S, Van Gelder IC, Wiesfeld AC, Van Veldhuisen DJ, Links TP 2011 Determinants and outcome of amiodarone-associated thyroid dysfunction. Clin Endocrinol (Oxf) 75:388-394.
586. Eskes SA, Endert E, Fliers E, Geskus RB, Dullaart RP, Links TP, Wiersinga WM 2012 Treatment of amiodaroneinduced thyrotoxicosis type 2: a randomized clinical trial. J Clin Endocrinol Metab 97:499-506.
587. Stan MN, Sathananthan M, Warnes CA, Brennan MD, Thapa P, Bahn RS 2014 Amiodarone-induced thyrotoxicosis in adults with congenital heart disease-clinical presentation and response to therapy. Endocr Pract 20: 33-40.
588. Bogazzi F, Bartalena L, Tomisti L, Rossi G, Brogioni S, Martino E 2011 Continuation of amiodarone delays restoration of euthyroidism in patients with type 2 amiodarone-induced thyrotoxicosis treated with prednisone: a pilot study. J Clin Endocrinol Metab 96:3374-3380.
589. Eaton SE, Euinton HA, Newman CM, Weetman AP, Bennet WM 2002 Clinical experience of amiodaroneinduced thyrotoxicosis over a 3-year period: role of colour-flow Doppler sonography. Clin Endocrinol (Oxf) 56:33-38.
590. Bartalena L, Brogioni S, Grasso L, Bogazzi F, Burelli A, Martino E 1996 Treatment of amiodarone-induced thyrotoxicosis, a difficult challenge: results of a prospective study. J Clin Endocrinol Metab 81:2930-2933.
591. Erdogan MF, Gulec S, Tutar E, Baskal N, Erdogan G 2003A stepwise approach to the treatment of amiodaroneinduced thyrotoxicosis. Thyroid 13:205-209.
592. Bogazzi F, Bartalena L, Cosci C, Brogioni S, Dell'Unto E, Grasso L, Aghini-Lombardi F, Rossi G, Pinchera A, Braverman LE, Martino E 2003 Treatment of type II amiodarone-induced thyrotoxicosis by either iopanoic acid or glucocorticoids: a prospective, randomized study. J Clin Endocrinol Metab 88:1999-2002.
593. Chopra IJ, Baber K 2001 Use of oral cholecystographic agents in the treatment of amiodarone-induced hyperthyroidism. J Clin Endocrinol Metab 86:4707-4710.
594. Daniels GH 2001 Amiodarone-induced thyrotoxicosis. J Clin Endocrinol Metab 86:3-8.
595. Huang CJ, Chen PJ, Chang JW, Huang DF, Chang SL, Chen SA, Jap TS, Lin LY 2014 Amiodarone-induced thyroid dysfunction in Taiwan: a retrospective cohort study. Int J Clin Pharm 36:405-411.
596. Lee KF, Lee KM, Fung TT 2010 Amiodarone-induced thyroid dysfunction in the Hong Kong Chinese population. Hong Kong Med J 16:434-439.
597. O'Sullivan AJ, Lewis M, Diamond T 2006 Amiodaroneinduced thyrotoxicosis: left ventricular dysfunction is associated with increased mortality. Eur J Endocrinol 154:533-536.
598. Patel N, Inder WJ, Sullivan C, Kaye G 2014 An audit of amiodarone-induced thyrotoxicosis-do anti-thyroid drugs alone provide adequate treatment? Heart Lung Circ 23:549-554.
599. Bogazzi F, Martino E, Dell'Unto E, Brogioni S, Cosci C, Aghini-Lombardi F, Ceccarelli C, Pinchera A, Bartalena L, Braverman LE 2003 Thyroid color flow doppler sonography and radioiodine uptake in 55 consecutive patients with amiodarone-induced thyrotoxicosis. J Endocrinol Invest 26:635-640.
600. Loy M, Perra E, Melis A, Cianchetti ME, Piga M, Serra A, Pinna G, Mariotti S 2007 Color-flow Doppler sonography in the differential diagnosis and management of amiodarone-induced thyrotoxicosis. Acta Radiol 48:628-634.
601. Macedo TA, Chammas MC, Jorge PT, Souza LP, Farage L, Watanabe T, Santos VA, Cerri GG 2007 Differentiation between the two types of amiodarone-associated thyrotoxicosis using duplex and amplitude Doppler sonography. Acta Radiol 48:412-421.
602. Bartalena L, Wiersinga WM, Tanda ML, Bogazzi F, Piantanida E, Lai A, Martino E 2004 Diagnosis and management of amiodarone-induced thyrotoxicosis in Europe: results of an international survey among members of the European Thyroid Association. Clin Endocrinol (Oxf) 61:494-502.
603. Oki GC, Zantut-Wittmann DE, de Oliveira Santos A, Guariento MH, Tambascia MA, de Almeida EA, Amorim BJ, Lima MC, Etchebehere EC, Camargo EE, Ramos CD 2010 Tc-99m sestamibi thyroid imaging in patients on chronic amiodarone treatment: a comparison with Tc-99m pertechnetate imaging. Clin Nucl Med 35:223-227.
604. Piga M, Cocco MC, Serra A, Boi F, Loy M, Mariotti S 2008 The usefulness of 99mTc-sestaMIBI thyroid scan in the differential diagnosis and management of amiodaroneinduced thyrotoxicosis. Eur J Endocrinol 159:423-429.
605. Tomisti L, Rossi G, Bartalena L, Martino E, Bogazzi F 2014 The onset time of amiodarone-induced thyrotoxicosis (AIT) depends on AIT type. Eur J Endocrinol 171: 363-368.
606. Osman F, Franklyn JA, Sheppard MC, Gammage MD 2002 Successful treatment of amiodarone-induced thyrotoxicosis. Circulation 105:1275-1277.
607. Uzan L, Guignat L, Meune C, Mouly S, Weber S, Bertagna X, Bertherat J, Thomopoulos P, Duboc D 2006 Continuation of amiodarone therapy despite type II amiodarone-induced thyrotoxicosis. Drug Saf 29:231-236.
608. Bogazzi F, Dell'Unto E, Tanda ML, Tomisti L, Cosci C, Aghini-Lombardi F, Sardella C, Pinchera A, Bartalena L, Martino E 2006 Long-term outcome of thyroid function after amiodarone-induced thyrotoxicosis, as compared to subacute thyroiditis. J Endocrinol Invest 29:694-699.
609. Broussolle C, Ducottet X, Martin C, Barbier Y, Bornet H, Noel G, Orgiazzi J 1989 Rapid effectiveness of prednisone and thionamides combined therapy in severe amiodarone iodine-induced thyrotoxicosis. Comparison of two groups of patients with apparently normal thyroid glands. J Endocrinol Invest 12:37-42.
610. Tanda ML, Piantanida E, Lai A, Liparulo L, Sassi L, Bogazzi F, Wiersinga WM, Braverman LE, Martino E, Bartalena L 2008 Diagnosis and management of amiodarone-induced thyrotoxicosis: similarities and differences between North American and European thyroidologists. Clin Endocrinol (Oxf) 69:812-818.
611. Bogazzi F, Bartalena L, Tomisti L, Rossi G, Tanda ML, Dell'Unto E, Aghini-Lombardi F, Martino E 2007 Glucocorticoid response in amiodarone-induced thyrotoxicosis resulting from destructive thyroiditis is predicted by thyroid volume and serum free thyroid hormone concentrations. J Clin Endocrinol Metab 92:556-562.
612. Houghton SG, Farley DR, Brennan MD, van Heerden JA, Thompson GB, Grant CS 2004 Surgical management of amiodarone-associated thyrotoxicosis: Mayo Clinic experience. World J Surg 28:1083-1087.
613. Williams M, Lo Gerfo P 2002 Thyroidectomy using local anesthesia in critically ill patients with amiodaroneinduced thyrotoxicosis: a review and description of the technique. Thyroid 12:523-525.
614. Meurisse M, Hamoir E, D'Silva M, Joris J, Hennen G 1993 Amiodarone-induced thyrotoxicosis: is there a place for surgery? World J Surg 17:622-626; discussion 627.
615. Pierret C, Tourtier JP, Pons Y, Merat S, Duverger V, Perrier E 2012 Total thyroidectomy for amiodaroneassociated thyrotoxicosis: should surgery always be delayed for pre-operative medical preparation? J Laryngol Otol 126:701-705.
616. Tomisti L, Materazzi G, Bartalena L, Rossi G, Marchello A, Moretti M, De Napoli L, Mariotti R, Miccoli P, Martino E, Bogazzi F 2012 Total thyroidectomy in patients with amiodarone-induced thyrotoxicosis and severe left ventricular systolic dysfunction. J Clin Endocrinol Metab 97:3515-3521.
617. Hermida JS, Tcheng E, Jarry G, Moullart V, Arlot S, Rey JL, Delonca J, Schvartz C 2004 Radioiodine ablation of the thyroid to prevent recurrence of amiodarone-induced thyrotoxicosis in patients with resistant tachyarrhythmias. Europace 6:169-174.
618. Izumi Y, Hidaka Y, Tada H, Takano T, Kashiwai T, Tatsumi KI, Ichihara K, Amino N 2002 Simple and practical parameters for differentiation between destruction-induced thyrotoxicosis and Graves' thyrotoxicosis. Clin Endocrinol (Oxf) 57:51-58.
619. Erdem N, Erdogan M, Ozbek M, Karadeniz M, Cetinkalp S, Ozgen AG, Saygili F, Yilmaz C, Tuzun M, Kabalak T 2007 Demographic and clinical features of patients with subacute thyroiditis: results of 169 patients from a single university center in Turkey. J Endocrinol Invest 30:546-550.
620. Benbassat CA, Olchovsky D, Tsvetov G, Shimon I 2007 Subacute thyroiditis: clinical characteristics and treatment outcome in fifty-six consecutive patients diagnosed between 1999 and 2005. J Endocrinol Invest 30:631-635.
621. Frates MC, Marqusee E, Benson CB, Alexander EK 2013 Subacute granulomatous (de Quervain) thyroiditis: grayscale and color Doppler sonographic characteristics. J Ultrasound Med 32:505-511.
622. Cappelli C, Pirola I, Gandossi E, Formenti AM, Agosti B, Castellano M 2014 Ultrasound findings of subacute thyroiditis: a single institution retrospective review. Acta Radiol 55:429-433.
623. Nishihara E, Ohye H, Amino N, Takata K, Arishima T, Kudo T, Ito M, Kubota S, Fukata S, Miyauchi A 2008 Clinical characteristics of 852 patients with subacute thyroiditis before treatment. Intern Med 47:725-729.
624. Kubota S, Nishihara E, Kudo T, Ito M, Amino N, Miyauchi A 2013 Initial treatment with 15 mg of prednisolone daily is sufficient for most patients with subacute thyroiditis in Japan. Thyroid 23:269-272.
625. Pearce EN, Farwell AP, Braverman LE 2003 Thyroiditis. N Engl J Med 348:2646-2655.
626. Mittra ES, McDougall IR 2007 Recurrent silent thyroiditis: a report of four patients and review of the literature. Thyroid 17:671-675.
627. Volpe R 1988 Is silent thyroiditis an autoimmune disease? Arch Intern Med 148:1907-1908.
628. Kamijo K 2010 Study on cutoff value setting for differential diagnosis between Graves' disease and painless thyroiditis using the TRAb (Elecsys TRAb) measurement via the fully automated electrochemiluminescence immunoassay system. Endocr J 57:895-902.
629. Nikolai TF, Coombs GJ, McKenzie AK, Miller RW, Weir GJ Jr 1982 Treatment of lymphocytic thyroiditis with spontaneously resolving hyperthyroidism (silent thyroiditis). Arch Intern Med 142:2281-2283.
630. Sicilia V, Mezitis S 2006A case of acute suppurative thyroiditis complicated by thyrotoxicosis. J Endocrinol Invest 29:997-1000.
631. Masuoka H, Miyauchi A, Tomoda C, Inoue H, Takamura Y, Ito Y, Kobayashi K, Miya A 2011 Imaging studies in sixty patients with acute suppurative thyroiditis. Thyroid 21:1075-1080.
632. Carney JA, Moore SB, Northcutt RC, Woolner LB, Stillwell GK 1975 Palpation thyroiditis (multifocal granulomatour folliculitis). Am J Clin Pathol 64:639-647.
633. Mai VQ, Glister BC, Clyde PW, Shakir KM 2008 Palpation thyroiditis causing new-onset atrial fibrillation. Thyroid 18:571-573.
634. Rudofsky G Jr, Grafe IA, Metzner C, Leowardi C, Fohr B 2009 Transient post-operative thyrotoxicosis after parathyroidectomy. Med Sci Monit 15:CS41-3.
635. Blazak JK, Ravi Kumar AS 2011 Palpation thyroiditis seen on F-18 FDG PET/CT. Clin Nucl Med 36:261-263.
636. Espiritu RP, Dean DS 2010 Parathyroidectomy-induced thyroiditis. Endocr Pract 16:656-659.
637. Stang MT, Yim JH, Challinor SM, Bahl S, Carty SE 2005 Hyperthyroidism after parathyroid exploration. Surgery 138:1058-1064; discussion 1064-1065.
638. Mammen JS, Ghazarian SR, Pulkstenis E, Subramanian GM, Rosen A, Ladenson PW 2012 Phenotypes of interferon-alpha-induced thyroid dysfunction among patients treated for hepatitis C are associated with pretreatment serum TSH and female sex. J Clin Endocrinol Metab 97:3270-3276.
639. Carella C, Mazziotti G, Amato G, Braverman LE, Roti E 2004 Clinical review 169: Interferon-alpha-related thyroid disease: pathophysiological, epidemiological, and clinical aspects. J Clin Endocrinol Metab 89:3656-3661.
640. Prummel MF, Laurberg P 2003 Interferon-alpha and autoimmune thyroid disease. Thyroid 13:547-551.
641. Koh LK, Greenspan FS, Yeo PP 1997 Interferon-alpha induced thyroid dysfunction: three clinical presentations and a review of the literature. Thyroid 7:891-896.
642. Babacan T, Sevinc A, Akarsu E, Balakan O 2012 Sunitinib-induced autoimmune thyroiditis in a patient with metastatic renal cell carcinoma: a case report. Chemotherapy 58:142-145.
643. Faris JE, Moore AF, Daniels GH 2007 Sunitinib (sutent)-induced thyrotoxicosis due to destructive thyroiditis: a case report. Thyroid 17:1147-1149.
644. Grossmann M, Premaratne E, Desai J, Davis ID 2008 Thyrotoxicosis during sunitinib treatment for renal cell carcinoma. Clin Endocrinol (Oxf) 69:669-672.
645. Jazvic M, Prpic M, Jukic T, Murgic J, Jaksic B, Kust D, Prgomet A, Bolanca A, Kusic Z 2015 Sunitinib-induced thyrotoxicosis-a not so rare entity. Anticancer Res 35:481-485.
646. Pinar D, Boix E, Meana JA, Herrero J 2009 Sunitinibinduced thyrotoxicosis. J Endocrinol Invest 32:941-942.
647. Sakurai K, Fukazawa H, Arihara Z, Yoshida K 2010 Sunitinib-induced thyrotoxicosis followed by persistent hypothyroidism with shrinkage of thyroid volume. Tohoku J Exp Med 222:39-44.
648. Iavarone M, Perrino M, Vigano M, Beck-Peccoz P, Fugazzola L 2010 Sorafenib-induced destructive thyroiditis. Thyroid 20:1043-1044.
649. Miyake H, Kurahashi T, Yamanaka K, Kondo Y, Muramaki M, Takenaka A, Inoue TA, Fujisawa M 2010 Abnormalities of thyroid function in Japanese patients with metastatic renal cell carcinoma treated with sorafenib: a prospective evaluation. Urol Oncol 28:515-519.
650. van Doorn L, Eskens FA, Visser TJ, van der Lugt A, Mathijssen RH, Peeters RP 2011 Sorafenib induced thyroiditis in two patients with hepatocellular carcinoma. Thyroid 21:197-202.
651. Bakerywala S, Schwarcz MD, Goldberg MD, Valiquette G, Weiss IA 2015 Nilotinib-associated destructive thyroiditis. Case Rep Endocrinol 2015:736092.
652. Barbesino G 2010 Drugs affecting thyroid function. Thyroid 20:763-770.
653. Bocchetta A, Cocco F, Velluzzi F, Del Zompo M, Mariotti S, Loviselli A 2007 Fifteen-year follow-up of thyroid function in lithium patients. J Endocrinol Invest 30:363-366.
654. Kirov G, Tredget J, John R, Owen MJ, Lazarus JH 2005A cross-sectional and a prospective study of thyroid disorders in lithium-treated patients. J Affect Disord 87:313-317.
655. McDermott MT, Burman KD, Hofeldt FD, Kidd GS 1986 Lithium-associated thyrotoxicosis. Am J Med 80:1245-1248.
656. Brownlie BE, Turner JG 2011 Lithium associated thyrotoxicosis. Clin Endocrinol (Oxf) 75:402-403.
657. Dwarakanathan AA 1998 Hyperthyroidism during lithium therapy for depression. Endocr Pract 4:201-203.
658. Onnestam L, Berinder K, Burman P, Dahlqvist P, Engstrom BE, Wahlberg J, Nystrom HF 2013 National incidence and prevalence of TSH-secreting pituitary adenomas in Sweden. J Clin Endocrinol Metab 98:626-635.
659. Malchiodi E, Profka E, Ferrante E, Sala E, Verrua E, Campi I, Lania AG, Arosio M, Locatelli M, Mortini P, Losa M, Motti E, Beck-Peccoz P, Spada A, Mantovani G 2014 Thyrotropin-secreting pituitary adenomas: outcome of pituitary surgery and irradiation. J Clin Endocrinol Metab 99:2069-2076.
660. Beck-Peccoz P, Brucker-Davis F, Persani L, Smallridge RC, Weintraub BD 1996 Thyrotropin-secreting pituitary tumors. Endocr Rev 17:610-638.
661. Rimareix F, Grunenwald S, Vezzosi D, Riviere LD, Bennet A, Caron P 2015 Primary medical treatment of thyrotropin-secreting pituitary adenomas by firstgeneration somatostatin analogs: a case study of seven patients. Thyroid 25:877-882.
662. Ross DS 1998 Syndromes of thyrotoxicosis with low radioactive iodine uptake. Endocrinol Metab Clin North Am 27:169-185.
663. Kung AW, Ma JT, Wang C, Young RT 1990 Hyperthyroidism during pregnancy due to coexistence of struma ovarii and Graves' disease. Postgrad Med J 66:132-133.
664. Goffredo P, Sawka AM, Pura J, Adam MA, Roman SA, Sosa JA 2015 Malignant struma ovarii: a population-level analysis of a large series of 68 patients. Thyroid 25:211-215.
665. Hershman JM 1999 Human chorionic gonadotropin and the thyroid: hyperemesis gravidarum and trophoblastic tumors. Thyroid 9:653-657.
666. Goodarzi MO, Van Herle AJ 2000 Thyrotoxicosis in a male patient associated with excess human chorionic gonadotropin production by germ cell tumor. Thyroid 10:611-619.
667. Pallais JC, McInnis M, Saylor PJ, Wu RI 2015 Case Records of the Massachusetts General Hospital. Case 38-2015. A 21-year-old man with fatigue and weight loss. N Engl J Med 373:2358-2369.
668. McCracken EJ, Johnston PC, Lindsay JR, Mulholland C, McAleer JJ, Black RN 2012 Testicular choriocarcinoma: an unusual case of paraneoplastic thyrotoxicosis. QJM 105:675-677.
669. Kang GY, Parks JR, Fileta B, Chang A, Abdel-Rahim MM, Burch HB, Bernet VJ 2013 Thyroxine and triiodothyronine content in commercially available thyroid health supplements. Thyroid 23:1233-1237.
670. Hedberg CW, Fishbein DB, Janssen RS, Meyers B, McMillen JM, MacDonald KL, White KE, Huss LJ, Hurwitz ES, Farhie JR 1987 An outbreak of thyrotoxicosis caused by the consumption of bovine thyroid gland in ground beef. N Engl J Med 316:993-998.
671. Shakir KM, Michaels RD, Hays JH, Potter BB 1993 The use of bile acid sequestrants to lower serum thyroid hormones in iatrogenic hyperthyroidism. Ann Intern Med 118:112-113.
672. Kreisner E, Lutzky M, Gross JL 2010 Charcoal hemoperfusion in the treatment of levothyroxine intoxication. Thyroid 20:209-212.
673. Kasagi K, Takeuchi R, Miyamoto S, Misaki T, Inoue D, Shimazu A, Mori T, Konishi J 1994 Metastatic thyroid cancer presenting as thyrotoxicosis: report of three cases. Clin Endocrinol (Oxf) 40:429-434.
674. Kopp P 2010 Thyrotoxicosis of other etiologies. In: De Groot LJ, Beck-Peccoz P, Chrousos G, Dungan K, Grossman A, Hershman JM, Kock C, McLachlan R, New M, Rebar R, Singer F, Vinik A, Weickert MO, eds. Endotext [Internet]. MDText. com, Inc., South Dartmouth, M.A.
675. Miyauchi A, Takamura Y, Ito Y, Miya A, Kobayashi K, Matsuzuka F, Amino N, Toyoda N, Nomura E, Nishikawa M 2008 3, 5, 3-Triiodothyronine thyrotoxicosis due to increased conversion of administered levothyroxine in patients with massive metastatic follicular thyroid carcinoma. J Clin Endocrinol Metab 93:2239-2242.
676. de Juan E Jr, Hurley DP, Sapira JD 1980 Racial differences in normal values of proptosis. Arch Intern Med 140:1230-1231.
677. Sarinnapakorn V, Sridama V, Sunthornthepvarakul T 2007 Proptosis in normal Thai samples and thyroid patients. J Med Assoc Thai 90:679-683.
678. Tsai CC, Kau HC, Kao SC, Hsu WM 2006 Exophthalmos of patients with Graves' disease in Chinese of Taiwan. Eye (Lond) 20:569-573.